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S u m á r i o 
 
A introdução da Anestesia na prática clínica permitiu a realização de tratamentos invasivos e 
procedimentos de diagnóstico. A generalização destas práticas levou a um aumento da 
exposição dos anestésicos gerais (AG) e consequentemente a uma maior preocupação 
sobre os seus efeitos nas funções cerebrais. Simultanemanente, os AG podem apresentar 
benefícios terapêuticos em condições clínicas particulares. Existe uma sobreposição entre os 
receptores com os quais os AGs interagem e os alvos farmacológicos no tratamento de 
vários distúrbios psiquiátricos. Estes fatos levaram a considerer a hipótese de que os AGs 
podem ter um papel na abordagem e na compreensão de patologias psiquiátricas. 
A Cetamina é um anestésico dissociativo, que para além das suas propriedades anestésicas 
também possui ação analgésica e antidepressiva. É também um potente modulador dos 
neurotransmissores glutamato e dopamina. Partindo das caraterísticas específicas deste AG, 
nós estabelecemos como principal objetivo do nosso trabalho investigar os efeitos da 
cetamina como potencial agente terapêutico em patologias do foro psiquiátrico. Do leque de 
patologias psiquiátricas, privilegiamos a patologia depressiva e o estudo da impulsividade. 
A patologia psiquiátrica, com maior relevo para a depressão major, é uma das doenças com 
maior prevalência na sociedade moderna. Durante as últimas décadas, o modelo de 
tratamento farmacológico da depressão foi construído com foco na reposição dos 
neurotransmissores monoaminérgicos, baseado fortemente na teoria monoaminérgica da 
depressão.  Os fármacos inibidores seletivos de recaptação da serotonina e os inibidores 
seletivos de recaptação da serotonina-noradrenalina têm como principal efeito o aumento da 
disponibilidade destes neurotransmissores. No entanto os antidepressivos utilizados na 
atualidade têm várias limitações, tais como: o inicio de ação muito lento que pode demorar 
semanas ou mesmo meses; a incapacidade de evitar novos episódios clínicos de depressão 
ou até mesmo o desenvovimento de resistência ao efeito antidepressor dos fármacos. Esta 
ineficácia terapêutica é um problema não apenas para o indivíduo, mas também para a 
sociedade. 
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O sistema glutamatérgico foi recentemente identificado como um potencial alvo. A exposição 
ao stress ambiental em modelos animais provoca uma libertação de glutamato nas areas 
límbicas e corticais, induzindo alterações estruturais muito semelhantes às observadas em 
pacientes deprimidos (Musazzi et al, 2011). A cetamina, é um antagonista dos receptores de 
glutamato e, apresenta uma ação antidepressiva rápida.  
Nesta tese é investigado o papel da cetamina como um tratamento co-adjuvante dos 
antidepressivos clássicos num contexto de depressão. Para testar tal hipótese, foi utilizado 
um modelo animal com comportamento semelhante ao depressivo, designado de “chronic 
mild stress”. O nosso trabalho produziu evidência de que a cetamina é capaz de induzir uma 
recuperação mais rápida no fenótipo anedónico quando foi associada ao tratamento com 
fluoxetina. Verificamos também que a nível morfológico a adição de cetamina aos 
antidepressivos (imipramina e fluoxetina) traduziu-se na recuperação das alterações 
provocadas pelo modelo, nomeadamente ao nível da maturação de espinhas dendríticas. 
Também detetamos uma alteração dos níveis de glutamato ao nível da região cerebral do 
nucleus accumbens, o que pode sugerir uma maior importância desta área do cérebro no 
efeito específico de cetamina quando administrada em conjunto com antidepressivos. 
Para além da ação glutamatérgica, a cetamina também aumenta agudamente os níveis de 
dopamina do cérebro. Existem vários distúrbios que são caracterizadas por um desequilíbrio 
da dopamina no cérebro e se traduzem em alterações comportamentais, nomeadamente do 
foro executivo e motivacional. Propusemo-nos então a investigar o efeito da cetamina num 
traço comportamental em particular: a impulsividade. Para esse efeito utilizamos um 
paradigma comportamental desenvolvido especificamente para avaliação de impulsividade 
em roedores: o Variable Delay to Signal Test. O nosso trabalho foi capaz de demonstrar que 
nos animais com exposição repetida a procedimentos anestésicos com cetamina ocorreu 
uma alteração do padrão de impulsividade. Além desse facto, desencadeou também 
alterações estruturais no nucleus accumbens assim como alterações ao nível da expressão 
dos recetores de dopamina no striatum.  
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Podemos afirmar que embora permaneçam por responder muitas questões relativamente ao 
potencial não-anestésico da cetamina, o nosso trabalho demonstrou uma potencial aplicação 
do fármaco como um potencial agente terapêutico em doenças psiquiátricas.  
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A b s t r a c t 
 
The introduction of general anesthesia in clinical practice allowed invasive treatment and 
diagnostic procedures. The generalization of these practices leads to an increased exposure 
to general anesthetics (GA) with increasing preoccupation about the effects of GA on brain 
function. While potential detrimental GA may have therapeutic benefits in particular clinical 
conditions. The overlap between the molecular targets of GA and drugs used to treat 
psychiatric disorders such as anxiety, depression and obsessive-compulsive disorder 
suggests that GA might have a therapeutic use in these conditions. 
Ketamine, in addition to its GA properties, is an analgesic, amnesic, and fast acting 
antidepressant, making it a very versatile molecule. The work presented in this thesis departs 
from this evidence to study Ketamine’s role as a behavioral modulator particularly in mood 
and motivational disorders. 
Mood disorders, such as major depression are highly prevalent in modern societies. During 
the last 50 years the pharmacological treatments of major depression has focused on the 
modulation of monoamine neurotransmission, including selective serotonin reuptake inhibitors 
(SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs). Despite a reasonable 
clinical efficacy these antidepressants have a slow onset and in some patients fail to respond 
at all. New targets and/or therapeutic molecules are therefore an urgent need. In this context, 
the glutamatergic system has recently been identified as a potentially interesting target. 
Exposure to environmental stressors in animal models enhance glutamate release in limbic 
and cortical areas and induce structural changes resembling those observed in depressed 
patients (Musazzi et al, 2011). Ketamine is an antagonist of glutamate receptors and 
possesses a fast antidepressant action. We investigated the potential role of ketamine as an 
adjuvant treatment to classical antidepressants in major depression. To test our hypothesis, 
we used an established animal depressive-like behavior animal model, the chronic mild stress 
(CMS). We observed that Ketamine was able to induce a faster recovery in the anhedonic 
phenotype when it was associated with treatment with fluoxetine. To clarify the neural 
substrates of such changes we conducted a detailed morphological analysis of the underlying 
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circuits. At a morphological level, the addition of Ketamine to antidepressants (imipramine 
and fluoxetine) translated in the recovery of the effects of the CMS model in dendritic spines 
maturation. We also detected a change in glutamate metabolism in the nucleus accumbens 
(NAc), which might suggest an essential role for this brain area in the specific effect of 
ketamine acting together with antidepressants. 
Ketamine can also acutely increase brain dopamine (DA) levels in the brain. There are 
several disorders which are characterized by an imbalance in brain DA and that are 
associated with a change in motivational behavior. In this line of thought, we proposed to 
investigate one specific behavioral trait of motivational behavior influenced by dopaminergic 
metabolism: impulsivity; more specifically how exposure to Ketamine can affect impulsive 
behavior.  
Through the novel behavioral paradigm developed in our laboratory, Variable Delay to Signal 
Test (VDS) paradigm, we were able to demonstrate that repeated exposure to ketamine 
anesthesia was able to change the impulsivity drive in animals after recovery from 
anesthesia. Moreover the exposure induced neuronal structural changes in the NAc and 
molecular changes in DA 2 receptor(DA2R) in the Striatum( Str).  
This thesis provides evidence for a role of Ketamine as a potential therapeutic agent in 
psychiatric disorders. 
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Anesthesia and Behavior 
 
General Anesthesia is a state of loss of both conscience and reactivity to noxic stimuli, 
produced by the action of general anesthetics (GA), characterized by the triad of analgesia, 
amnesia and immobility. The introduction of GA in clinical practice provided an invaluable 
contribution to the advance of healthcare, allowing the performance of complex and invasive 
surgical and diagnostic procedures. In fact, according to the World Health Organization 
(WHO, 2009) no single improvement in the care of surgical patients has had a profound 
impact as the advancement of safe practices in anesthesia, highlighting the importance of the 
study of GA.  
Ancient cultures already used substances, such as alcohol and opioids, to induce states of 
lethargy. For instance, the Sumerians and ancient Egyptians were known to harvest Papaver 
somniferum (Bisset et al, 1994) to produce opium, and the Inca are also known for the use of 
coca leaves in traditional medicine.  
The concept of GA applied surgical procedures appeared later in the 19th century. In 1886, 
William T. G. Morton was the first to report the accomplishment of an anesthetic procedure 
using ether (Greene et al, 1979). 
 
Safety of using general anesthetics 
 
Developments in both pharmacology knowledge and the establishment of standardized 
procedures transformed anesthesiology into a medical field driven by safety improvement 
(Botney et al, 2008). The first true attempt to access mortality numbers of anesthesia was the 
Beecher-Todd anesthesia death rate study (Beecher et al, 1954). Several others studies have 
since been reported (Bainbridge et al, 2012; Watters et al, 2015) showing that anesthesia 
procedures are one of the safest medical activities with very low intraoperative mortality rates 
due to anesthetic procedures (Li et al, 2009; Newland et al, 2002)  
However, continuous focus on patient safety assessment shows us that there is always room 
for improvement. Recently, Glance and colleagues observed that patient outcomes may be 
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affected by different intraoperative anesthetic management strategies (Glance et al, 2015), 
highlighting the importance of tailored choices of anesthetic procedures. 
Other focus is on professional exposure to general anesthetics, which mainly concerns 
inhalational agents. In order to prevent this issue, legislation on scavenging anesthetic gases 
and on air quality was implemented. Specifically, some agents considered to be hazardous to 
public health stop being used.  
Despite the improvements there are several GA related issues that require immediate 
attention such as effects on patient’s brain or misuse by health professionals. We will further 
develop these subjects on the following sections. 
 
Evidence of general anesthetics effects in brain 
 
The classical pharmacokinetic concept of a GA is that as long as the drug is eliminated, its 
effects will disappear, and normal brain function is restored.  
Anesthesia is known to have effects in the connectivity between different brain regions. The 
effects on cortico-cortical connectivity is varied, depending on the anesthetic agent and the 
specific network examined; however, fronto-parietal connectivity is often reduced in 
anesthesia.  
Most studies focus on the moment of loss of consciousness during general anesthesia and 
research suggests that the networks based on the posterior parietal-cingulate-precuneus 
region and the thalamus are candidates for the neural correlate of the state of consciousness 
(Alkire et al, 2008).  
In light of increasing safety and reduced mortality with the use of GA, more recently, the 
discussion moved towards the effects of GA in brain function, in particular, the effects of GA 
in both the healthy and ageing brain.  
Most studies on the effect of GA in diseased brain were performed in order to answer if 
exposure could trigger or be related to diseases such as Alzheimer’s disease in elderly or 
attention deficit hyperactivity disorder in children (Culley et al, 2007; Sprung et al, 2010), 
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however there is no direct cause-effect relation between those pathologies and GA exposure 
(Planel et al,2007; Hansen et al; 2015).  
Other field of research focus in the assessment if exposure of developing brain to GA could 
induce changes. A bulk of preclinical data suggests that exposure to commonly used 
anesthetic agents during key periods of brain development can lead to neurodegeneration, 
synaptic loss and  learning and memory deficiencies that might persist as the organism 
matures (Jevtovic-Todorovic et al, 2003; Lunardi et al, 2010) In addition, neonatal anesthetic 
exposure in in vivo models was confirmed to change neurogenesis and synaptogenesis 
processes, indicating that GA might influence neuroplasticity as well (De Roo et al, 2009; 
Briner et al, 2010)  
 
Throughout this thesis we will focus in a different concept, targeting adult brain and exploring 
long lasting effects in specific brain functions after GA exposure.  
 
The influence of general anesthetics on mood disorders 
 
The effect of GA on mood is a relatively new field of knowledge (Rasmussen et al, 2003; 
Poulsen et al, 2018). The overlap between GA targets in brain and the targets of drugs used 
to treat psychiatric disorders open the pathway to the hypothesis that GA exposure might 
somehow have an effect in patient’s mood. 
Anesthetics are thought to work by interacting with ion channels that regulate synaptic 
transmission and membrane potentials in key regions of the brain and spinal cord, such as 
neurotransmitter receptors. These ion-channel targets are differentially sensitive to various 
anesthetic agents. Anesthetics hyperpolarize neurons by increasing inhibition or decreasing 
excitation (Ries et al, 1999) and, consequently, alter neuronal activity: The sustained firing 
typical of the aroused brain changes to a bistable burst-pause pattern (Llinás et al, 2006) that 
is also observed in sleep. 
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The specific case of Ketamine 
 
Ketamine (2-chlorphenyl-2-methylamino-cyclohexanone) was first synthesized by Calvin 
Stevens of the Parke-Davis pharmaceutical company in 1962 and formally described in 1965 
(Domino et al, 1965). 
Ketamine is recognized as a dissociative anesthetic (Domino et al, 1966), with additional 
analgesic, amnesic, and fast acting antidepressant properties (Berman et al, 2000; Zarate et 
al, 2006). Ketamine is used as a general anesthetic both in human and veterinary medicine 
(Green et al, 1981).  
Ketamine’s two enantiomers, (R)-ketamine and (S)-ketamine, have different pharmacological 
properties, as well as differential effects on psychiatric symptoms and cerebral metabolism in 
healthy volunteers (Oye et al, 1992; Vollenweider et al, 1997). (S)- ketamine has a higher 
affinity for the N-methyl-D-aspartate (NMDA) receptors PCP binding site than (R)-ketamine by 
a factor of 4–5:1. Whereas (R)-ketamine does not significantly alter scores on psychiatric 
assessments, (S)-ketamine produces symptoms of depersonalization, derealisation, visual 
disturbances, thought disorders, and apathy (Vollenweider et al, 1997). 
The influence of ketamine on central nervous system as a GA has been investigated with 
various imaging techniques, including positron emission tomography and task-related 
functional magnetic resonance imaging, with several brain regions displaying ketamine-
dependent activity changes, such as the prefrontal cortex (PFC), ventral tegmental area, 
substantia nigra in midbrain, posterior cingulate cortex, visual cortex, insular cortex and 
thalamus (Rogers et al; 2004; Schmidt et al, 2005;  Nagels et al, 2011, Yu et al, 2012). 
Additionally, the effect of ketamine, specifically sub-anesthetic doses in brain connectivity is 
now being subject of study. Sub-anesthetic doses of ketamine were found to increase the 
connectivity in the cerebellum and visual cortex, and to induce a decrease in connectivity in 
the auditory and somatosensory network in relation to several regions, which included the 
amygdala, insula, and anterior cingulate cortex (Niesters et al, 2012). Acute ketamine 
treatment was also found to increase PFC metabolic activity while reducing metabolic activity 
in the dorsal reticular thalamic nucleus, in association with an abnormal functional 
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connectivity between the PFC and multiple thalamic nuclei, including the dorsal reticular 
thalamic nucleus, mediodorsal thalamus and anteroventral thalamus (Dawson et al, 2013). 
One recent study (Dawson et al, 2014) found that acute NMDA receptor blockade with 
ketamine promotes increased connectivity in functional brain networks, namely, that acute 
ketamine treatment enhances connectivity of PFC and thalamic brain regions in brain 
networks, with enhancement of PFC neuromodulatory subsystem connectivity in animals. 
Other work exploring the effects of different sub-anesthetic doses of ketamine showed dose- 
and exposure-dependent increases in functional connectivity within the PFC and in anterior–
posterior connections between the posterior hippocampus and retrosplenial cortex, and PFC 
regions (Gass et al, 2004). 
Curiously, while GA produce a substantial and global reductions in cerebral metabolic rate 
and in cerebral blood (Alkire et al, 1995; Alkire at al, 1997; Alkire et al, 1999), ketamine has 
the opposite effect increasing cerebral metabolic rate in most brain regions (Langsjo et al, 
2005). 
It is not completely clear if these characteristics are responsible for the antidepressant effect 
of ketamine.   
 
 
Major Depression/Depressive disorders 
 
Depression is a heterogeneous disorder with a variable course, an inconsistent response to 
current treatment and a pathophysiological mechanism that is still poorly understood. The 
diagnose of major depressive disorder requires a distinct change of mood, characterized by 
sadness or irritability and accompanied by at least several psychophysiological changes, 
such as disturbances in sleep, appetite, or sexual desire; loss of the ability to experience 
pleasure in work or with friends; crying; suicidal thoughts; and slowing of speech and action. 
These changes must last a minimum of 2 weeks and interfere considerably with work and 
family relations (American Psychiatric Association, 2013). 
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Depression is likely to be a multifactorial disease. Concerning genetic factors, most of the 
evidences comes from twin studies. Some studies show an estimated heritability of MD at 
38% (Kendler et al, 2006). Environmental factors and genetics both seem to play a role in the 
etiology of MD (Saveanu et al, 2012). Several theories have been developed in the last years 
trying to explain the mechanism that underlies this complex disease.  
 
 
The monoaminergic theory of depression 
 
The monoamine theory was raised in 1960´s upon early empirical clinical observations and it 
postulates that a deficiency of monoamine (serotonin and norepinephrine) neurotransmission 
in the brain is the main cause for depression. This is corroborated by the observation that 
monoamine enhancing drugs (e.g. cocaine) quickly improve humor and monoamine depleting 
drugs (e.g. reserpine) lead to the rapid establishment of depressive humor (Krishnan et al, 
2008). Monoaminergic neurotransmission is mediated by serotonin (5-hydroxytryptamine 1A 
and 5-hydroxytryptamine 1B) or norepinephrine (noradrenaline) released from presynaptic 
neurons. The synthetic pathway of serotonin starts with the catalytic action of tryptophan 
hydroxylase on tryptophan; norepinephrine is synthesized from tyrosine, with the first step 
being catalyzed by tyrosine hydroxylase. After synthesis, both monoamine transmitters are 
stored in vesicles in the presynaptic neuron and released into the synaptic cleft on demand. 
Upon release, monoamines act in receptors both in pre- and post-synaptic neurons. The 
activity of monoamines is terminated by local metabolism and reuptake to the pre-synaptic 
neuron through specific transporter proteins (NET for norepinephrine and SERT for 
serotonin). Additionally, the activity on pre-synaptic receptors works as a negative feedback 
system reducing the release of further neurotransmitter. Findings in patients with depression 
that support the monoamine-deficiency hypothesis include the relapse of depression with 
inhibition of tyrosine hydroxylase or depletion of dietary tryptophan, increased frequency of a 
mutation affecting the brain-specific form of tryptophan hydroxylase (TPH-2) in patients, 
increased specific ligand binding to MAO-A, subsensitive 5-HT1A receptors, malfunctioning 5-
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HT1B receptors, decreased levels of p11, polymorphisms of the serotonin-reuptake 
transporter associated with depression, an inadequate response of G proteins to 
neurotransmitter signals, and reduced levels of cAMP, inositol, and CREB in postmortem 
brains (Nutt et al, 2002).  
A strong point of the monoamine theory has been its predictive power. Almost every 
compound that has been synthesized for the purpose of inhibiting norepinephrine or serotonin 
reuptake has been proved to be a clinically effective antidepressant, demonstrated in the 
Forced Swim Test (a behavioral test specifically designed and validated to evaluate rodents 
learned helplessness) (Porsolt et al, 1978). A single prior injection of antidepressant 
increases the struggling time in the forced swimming test; results in this model have excellent 
predictive validity when applied to new antidepressants.  
The effects of stimulants on mood indirectly support the monoamine-deficiency hypothesis of 
depression and show that mood can be altered rapidly. Cocaine and amphetamines are 
powerful releasers of monoamines into the synapse as well as inhibitors of reuptake (Sitte et 
al, 2015). Their mood-elevating effects are immediate, but in patients with severe depression 
they have often been reported to cause agitation rather than relief of depression (Post et al, 
1978). This finding could reflect the additional ability of these stimulants to deplete the 
presynaptic monoamines and thus cause depression.  
The role of DA deficiency in depression is suggested by the frequency of depression in 
patients with Parkinson’s disease (PD) (which is characterize by a massive loss of 
dopaminergic neurons) and the effect of reserpine, which depletes serotonin, norepinephrine, 
and DA, causing a hypoactive state in animals (Santiago et al, 2014). The antidepressant 
agent buproprion inhibits the reuptake of DA reinforcing the clinical aspect of DA in 
depression (Stahl et al, 2004).  
 
Current standard of major depressive disorders treatment 
 
The standard of care in pharmacological treatment of major depression for the last 50 years 
has focused on monoamine neurotransmission modulation, including such treatments as 
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SSRIs and SNRIs. Both treatment and development of new drugs have been heavily based in 
the monoamine theory (Schildkraut et al, 1995; Racagni et al, 2008).  
A major problem of the monoamine hypothesis is the lack of pharmacological treatment 
efficiency.  Currently available antidepressants were developed in order to increase the 
availability of monoamines; however, treatment modalities suffer from drawbacks such as 
slow onset of clinical effects and limited efficacy in treatment-resistant cases as well as a 
considerable placebo effect. Approximately only two thirds of patients have a clinical 
response to these agents and one third have antidepressant response to placebo treatment.  
The limited efficacy of treatment imposes substantial burdens on the affected individuals as 
well as on public health and society. Perhaps the monaminergic hypothesis cannot explain 
the mechanism of all depressive disorders. Further mechanisms must be explored with the 
objective to improve knowledge and therapeutic approach to major depression. 
 
Glutamate: a new promise in depression treatment? 
 
Glutamatergic synaptic transmission in the mammalian central nervous system was 
established in the 1950s and later described as the most important one in excitatory 
neurotransmission in brain (Orrego et al, 1993). Glutamate neurons and synapses outnumber 
by far most of the other neurotransmitter systems with the exception of GABA. In the early 
1980s, NMDA receptors were shown to be involved in several central synaptic pathways, 
acting together with non-NMDA receptors under conditions where an excitatory postsynaptic 
potential was elicited in response to intense stimulation of presynaptic fibres (Watkins et al, 
2006). 
In the matter of neurotransmission, brain can be drawn mainly as a glutamatergic excitatory 
system in competition with a smaller GABAergic inhibitory system that is modulated by a 
smaller population of heterogeneous neurons releasing several other neurotransmitters, such 
as the example of neuroamines. The fast regulation of neurotransmission by monoamines is 
responsible for the modulation of several brain functions such as sleep or motivational 
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behavior. However, it is the equilibrium between excitatory and inhibitory transmission that 
mediates most brain functions.  
Glutamatergic neurotransmission, present throughout the brain, is responsible for the 
establishment of a balanced and regular connectivity between different brain areas.  
Depressed patients are known to have an imbalance in glutamatergic system, and the 
antidepressant response is also accompanied by changes in glutamatergic system. 
Measurements of glutamate and its metabolites in depressed patients revealed changes in 
several body compartments: there seems to be a trend for increase in glutamate and 
decrease in glutamine/glutamate ratio in the plasma of patients with depressive disorders 
when compared with healthy patients  (Kim et al, 1982; Mauri et al, 1998; Mitani et al, 2006; 
Kuçukibrahimoglu et al, 2009);  there are reports of reduced glutamate in Cerebral Spinal 
Fluid (CSF) in individuals with major depressive and bipolar disorder (Frye et al, 2007); and 
post mortem histopathology and magnetic resonance imaging analysis of studies of 
depressed patients are in line with the information above (Campbell et al, 2006; Lorenzetti et 
al, 2009; Hashimoto et al, 2007). 
  
The use of NMDA receptor antagonists in major depression treatment has been defended 
since 1990s, when early reports suggested that NMDA receptor antagonists showed 
antidepressant-like action (Trullas et al, 1990). Nowadays, none of the approved 
antidepressants administrated directly targets specifically the glutamatergic system but novel 
compounds are being explored with that purpose (Agbo et al, 2017; Sanacora et al, 2017). 
Extensive preclinical characterization of the effects of ketamine has partially clarified its 
mechanism of action, though how ketamine’s activity is linked to known pathophysiological 
changes in depression has just begun to be understood. The glutamate hypothesis is 
expected to complement the monoamine hypothesis of mood disorders. 
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Morphologic correlates of depressive models 
 
Analysis of brain volume areas in neuroimaging studies revealed changes in brains of 
patients with psychiatric disorders, mood, anxiety and depression (Konarski et al, 2006; 
Lorenzetti et al, 2009; Koolschijn et al, 2009). An imbalance in neural activity within large-
scale networks appears to be an important pathophysiological aspect of depression. Major 
depressive disorder has been associated with abnormal resting-state functional connectivity, 
especially in cognitive processing and emotional regulation networks. 
The default mode network (Collin et al, 2014, Stevens et al, 2010), a key network activated 
during rest and thought to reflect self-directed thinking, has frequently been found to show 
increases in regional cerebral blood flow (Lui et al, 2011), cerebral glucose metabolism (Mah 
et al, 2007), and functional connectivity (Sheline et al, 2010; Zhu et al, 2012; Li et al, 2013) in 
depressed patients. These increases of default mode network connectivity suggest their 
strengthened roles in coordinating information transfer in brain networks, which may reflect 
pathologic adaptations.  
Using resting-state functional brain imaging techniques, researchers have shown that major 
depression is associated with hypoactivity in cognitive control brain regions, especially 
pregenual anterior cingulate, posterior cingulate, and middle frontal gyri and affective control 
cortical regions such as insula (Sawaya et al, 2015). Regions considered overactive in major 
depression include deeper brain structures such as the thalamus and caudate, among others 
(Fitzgerald et al., 2008). Investigators have also observed increases in functional connectivity 
of the posterior cingulate cortex with the orbitomedial pre-frontal cortex and dorsolateral pre-
frontal cortex in acute depression (Zhou et al., 2010) and of the posterior cingular cortex with 
the medial temporal lobe in remitted depression (Wu et al., 2013). Findings of reduced 
functional connectivity are most frequently found between cortical and subcortical regions, for 
example between the anterior cingulate cortex, medial thalamus and pallidostriatum (Anand 
et al., 2005), the ventromedial pre-frontal cortex, and the cerebellum (Liu et al, 2012), and the 
middle frontal gyrus with the hippocampus (Cao et al, 2012). Together, these R-fMRI studies 
suggest topological disorganization of brain functional networks in depression. Given some 
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inconsistent findings among studies there is need for further validation of all these findings. 
However functional dysconnectivity has been reported when depressed patients perform 
specific emotional or cognitive tasks (Frodl et al, 2010; Versace et al, 2010). All these works 
show us that system-level disruption of functional brain networks underlies the mood and 
cognitive impairments associated with depression, and the regulation of connectivity might be 
a target to improve treatment. 
Depressed patients seem to have a decrease in brain volumes in frontal regions such as the 
PFC, orbitofrontal cortex, the anterior cingulate, the hippocampus and Str (Grieve et al, 
2013). Additionally, the structural changes in neuron dendrites are widely studied in 
preclinical models of stress models which induce depressive like behavior animal models: 
several models of stress have been shown to induce atrophy, retraction and consistently 
reproduced remodeling of dendrites in pyramidal neurons of CA3 hippocampal region, in 
medial PFC and orbitofrontal cortex (Michelsen et al, 2007; Cerqueira et al, 2007). The 
dendritic remodeling induced by stress was reversible after cessation of the exposure to 
stressors, or after pharmacological treatment (Bessa et al, 2009). In other areas, such as the 
amygdala and the NAc, stress induced an increase in dendritic length (Vyas et al, 2002; Pego 
et al, 2006; Bessa et al, 2013). Evidences in rodent studies suggest that stress is a powerful 
factor in remodeling neuronal architecture, synaptic connections and circuits.  
In summary, volumetric alterations are known to take place in brain regions associated to 
functional changes in depressed patients. The common feature in all these structural changes 
is occurrence of an overlap between brain areas with volumetric changes and regions where 
there is a decrease in glial cell population and neuronal structural changes in depressed 
patients (Rajkowska et al, 2002). These data seem to support that changes in glutamate 
metabolism and synaptic function might be correlated and might be responsible for the 
dendritic remodeling and tissue morphological changes found in depressive disorders. The 
use of animal models of stress-induced depressive-like behavior has shown that 
environmental stress enhances glutamate release and reduce glutamate cycling. The 
exposure of animals to acute stressors such as tail-pinch or restraint, or the administration of 
corticosterone produced a rapid increase in the levels of extracellular glutamate measured by 
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in vivo microdialysis in different brain areas, such as the hippocampus, amygdala or PFC 
(Moghaddam et al, 1993; Reznikov et al, 2007).  
 
 
Impulsivity 
 
Impulsivity can be defined as “a predisposition towards rapid unplanned reactions to internal 
or external stimuli with reduced regard to the negative consequences of these reactions to the 
individual or to others” (Moeller et al, 2001). Impulsivity is not a unitary construct and it can 
manifest itself as several behaviors, which include the tendency to act without thinking, on the 
urge of the moment, the inability to delay gratification, distractibility or the difficulty in the 
inhibition of incorrect or inappropriate responses. Changes in impulsive behavior have been 
observed in several mental illnesses. These phenomena can lead to harmful behaviors, 
including violence, and thus represent a serious public health concern.  
Impulsive behavior has been grouped in two subclasses: 1) decision impulsivity, when the 
actions are initiated without due deliberation of other possible options or outcomes and 
associated with an increased preference for (smaller) immediate rewards over more 
beneficial delayed rewards; and 
2) response impulsivity when actions are premature and difficult to suppress or control, often 
related to the inability to inhibit an initiated response.  
 
 
Impulsivity measurement 
 
The gold standard for measuring decision impulsivity is the delay discounting (Evenden et al, 
1996), and for response impulsivity is the 5-choice serial reaction time task (Carli et al, 1983). 
Both paradigms are laborious to establish with very long learning curves that lend them 
unsuitable for testing acute effects of drugs. A new experimental paradigm, designated 
Variable Delay to Signal (DVS) paradigm, was developed to measure impulsive behaviour in 
	 28 
rodents which provides an effective assessment for both response and decision impulsivity 
(Leite-Almeida et al, 2013). In this task, animals are required to detect and respond to light 
stimuli presented in one single hole. The animal then indicates the perception of the stimuli by 
nose-poking the hole. Correct responses are awarded with a food pellet in a dispenser, while 
incorrect responses cause a time out period. Failure of the animal to wait for the stimuli to 
respond produces premature responses. In the VDS paradigm, during the test phase the 
animal is exposed to a period of variable delays to the stimuli, providing a fast-
multidimensional assessment of impulsive behaviour with fewer burdens to the animals 
(Chapter 3). 
 
 
Neural subtracts of impulsive behaviour 
 
Significant research has been developed in the last years regarding the identification of the 
brain areas that could be specifically relevant for the impulsivity behavior. In this line of 
thought, it was identified that brain areas including PFC, Str and NAc (McClure et al, 2004; 
Tamm et al, 2004) were involved in impulsivity behavior. The PFC was determined to be 
involved in the performance of tasks that require behavioral inhibition and in tasks implying 
variation in delay to perform an action (McClure et al, 2004). Beyond frontostriatal circuits, 
two other circuits were suggested to be particularly important to impulsivity, namely, a reward-
discounting circuit where a ventral striatal loop involves the ventral medial PFC, the 
subgenual cingulated cortex, and the NAc/ventral Str, and a motor control circuit including the 
ventrolateral PFC, the anterior cingulate, and the presupplementary motor and their link to the 
caudate nucleus and putamen (Kim et al, 2013).  
In healthy individuals, stronger ventral Str-seeded connectivity predicted reduced impulsivity 
in everyday life (Gordon et al, 2015). In juvenile subjects, impulsive-irresponsible traits were 
associated with altered connectivity patterns in the fronto-parietal cognitive control networks 
(Cohn et al, 2015). Many studies have implicated dysfunctional frontotemporal circuitry in 
impulsivity and aggression in schizophrenia. In patients with cocaine dependence there is a 
	 29 
correlation between impulsivity and cortical connectivity of Orbitofrontal–subgenual cingulate 
cortex (Contreras-Rodríguez et al, 2015), however, the association between network changes 
and impulsivity is not exclusive to pathological subjects. All these works also show us that 
impulsive trait, in healthy or diseased subjects, is related with changes in brain connectivity. 
 
 
Neurotransmitters in impulsivity 
 
Wide ranges of disorders, such as attention deficit/hyperactivity, substance abuse or 
pathological gambling are characterized by changes in impulsivity. These pathologies also 
have in common DA changes (Buckholtz et al, 2010). To reinforce this observation, Catalan 
and colleagues later reported that patients of DA related-medical conditions, such as PD, 
showed impulsive behavioural changes after being treated with DA agonists (Catalan et al, 
2013). 
Evidence for the involvement of the dopaminergic system in impulsivity was initially 
suggested following the identification of receptor gene variants in attention deficit 
hyperactivity disorder (Gadow et al, 2008). More specifically it was observed that DA plays a 
paramount role in the development and function of frontostriatal circuits and for value based 
decisions-making (Volkow et al, 2009). Runia and colleagues have demonstrated that DA is 
also important for attention processes (Rubia et al, 2009). 
DA neurotransmission is also affected by GA and it may lend subjects more prone to 
impulsive/risky behavior. This subject is further explored in chapter 1. 
Serotonine (5-HT) was also observed to be important in impulsive behavior. Further 
investigation of attention deficit hyperactivity disorder, Oades and colleagues were able to 
establish an inverse correlation between the role of this neurotransmitter levels and the 
impulsive traits in different spectrum of the disease (Oades et al,2008). 
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C o n t e x t  o f  t h e  w o r k  a n d  A i m s  
 
The study of potential long-term effects of exposure to the GA focused on determining the 
role of GAs exposure to the deterioration of brain functions. Following the above, Ketamine is 
an interesting study topic both in the perspective of GAs as well as antidepressants.  
The main action of ketamine is at the level of the NMDA receptors as a noncompetitive 
antagonist, but it also interacts with DA and serotonin receptors. For clinical application, the 
ketamine is a drug with a broad spectrum of effects: at low doses has analgesic and 
antidepressant action, at higher doses induced psychotic effects, and at high doses induces 
anesthesia. The versatility of ketamine makes it a drug with great potential in the study and 
design of new therapeutic approaches in several pathologies. The potential as an 
antidepressant as well as the effect of ketamine in modulating circuits important for 
motivational behavior were the reasons that led us to develop the experimental work leading 
to the preparation of this thesis.  
Our laboratory has a long tradition in the study of the effects of stress. The study developed in 
our laboratory on the effects of stress is multidisciplinary and involves not only the study of 
the changes triggered by stress (Pego et al, 2008, Cerqueira et al,2007) but also the 
evaluation of potential therapies (Bessa et al, 2009). Previously the morphological changes 
induced by chronic stress models were identified (Cerqueira et al, 2007), as were also 
evaluated the effects of drugs in reversing them (Bessa et al, 2009; Bessa et al, 2013). There 
is also an extensive work in developing new paradigms for the evaluation of animal behavior. 
(Leite-Almeida et al, 2013; Morgado et al, 2014).  
In order to combine the experience of the working group with the study of a drug that looks 
promising, the main objectives we set in the development of this thesis were: 
 
§ Identify the effect of ketamine as an adjuvant to the classical antidepressants in the 
response to treatment in an animal model of induced depressive like behavior. 
§ Evaluate the effects of ketamine on the reversal of neuronal morphological changes 
induced in the animal model of depressive like behavior 
	 32 
§ Assess the effects of ketamine on glutamatergic dynamic in key areas affected by 
animal model of depressive like behavior. 
§ Assess the long-lasting effects of ketamine in impulsive behavior when used in 
anesthetic doses and in repeated GA procedures. 
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General anesthetics (GA) are well known for the ability to induce
a state of reversible loss of consciousness and unresponsiveness to
painful stimuli. However, evidence from animal models and clini-
cal studies show that GA exposure may induce behavioral
changes beyond acute effects. Most research and concerns are
focused on changes in cognition and memory. We will look at
effects of GA on behavior that is mediated by the dopaminergic
system. Pharmacological resemblance of GA with drugs of abuse,
and the complexity and importance of dopaminergic systems in
both reward seeking and addictive illnesses make us believe that
it deserves an overview about what is already known and what
matters to us as healthcare workers and specifically as anesthesi-
ologists. A review of available evidence strongly suggests that
there may be a link between the effects of GA on the brain and
substance abuse, partly explained by their influence on the dopa-
minergic system.
Editorial comment: what this article tells us
This review article points out that general anesthesia may induce behavioral changes mediated via
the dopaminergic system, and that some of the same mechanisms may be involved in substance
abuse and reward seeking behavior.
Development of new drugs and technics in
anesthesia was of paramount importance to the
revolution of modern medicine. The pursuit of
the ultimate perioperative homeostatic balance
and increased awareness of safety issues
allowed us to achieve lower levels of morbidity
and mortality as standard of care.1
We have used GA regularly since 1846, but
we have not been able to build a complete the-
ory that unifies both the molecular effects and
the behavioral response of loss and gain of con-
sciousness. The first theory (Meyer–Overton cor-
relation) stated that lipid solubility of GA was
responsible for their anesthetic effects.2 When
Acta Anaesthesiologica Scandinavica (2015)
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such a generalistic statement failed to explain
how GA work, then the paradigm moved look-
ing for specific molecular targets. The discovery
that GA could interact with the firefly luciferase
enzyme directed research toward proteic tar-
gets.3 Today, we know that GA target neuro-
transmitter receptors in the whole brain,
inducing fast modulation of membrane poten-
tials and neuronal cell firing, as well as slower
modulation of second messenger cascades and
protein synthesis compounds that are responsi-
ble for fast behavioral changes involving arou-
sal, memory, nociception and fear. Additionally,
research has shown us that exposure to GA can
also be responsible for changes that are not so
short-lived.
Reports of temporary cognitive impairment
and long-term neurodevelopmental impairment
in animal models of anesthetic exposure4–6 as
well as clinical reports of decline in cognitive
performance after surgery/anesthesia in
humans7,8 brought an old question to the
spotlight: can GA exposure change the way
we subsequently behave? Now we know that
factors such as surgical procedure together
with individual factors influence patient cogni-
tive outcome9,10 and that exposure to GA
alone has not been proven to be responsible
for cognitive impairment in humans, even in
groups thought to be particularly susceptible
such as children.11 Most research is focused
on cognitive processes, but one particular clin-
ical study, the ISPOCD, reported both higher
risk of prematurely leaving labor market and
of dependence on social transfer payments in
patients who developed postoperative cognitive
dysfunction,12 suggesting that impairment may
extend beyond cognition. Do GA exert a more
subtle influence on us, not necessarily through
a decline in cognition? To answer this particu-
lar questions, we will focus our discussion on
other dimensions of behavior. The molecular
resemblance of GA with drugs of abuse and
the misuse of GA for recreational purposes13
raise concerns about the possible role of GA
as agents that induce changes in motivational
behavior. From all the neurotransmitters that
are targeted by GA, dopamine (DA) is the
most important in motivational and reward
circuitries, with a strong role in conditioning
behaviors. In this review, we will focus on
the possible link between the effects of GA
and drug abuse and how these mechanisms
may help explain some of the potential effects
of GA on the brain.
Understanding the role of dopamine
DA is a catecholaminergic neurotransmitter
present both in the central nervous system and
in several other tissues such as the cardiovascu-
lar and digestive systems. DA is synthesized by
the hydroxylation of the amino acid L-tyrosine
to L-DOPA by tyrosine hydroxylase (TH) which
is further converted to DA by DOPA decarbox-
ylase (or aromatic L-amino acid decarboxylase).
DA is stored in vesicles in the presynaptic ter-
minal by the action of vesicular monoamine
transporter. DA release from dopaminergic neu-
rons into the synaptic cleft is achieved either
through a calcium-dependent exocytic process
similar to other neurotransmitters or through
membrane DA transporter (DAT). Once in the
synaptic cleft, DA binds to and activates DA
receptors (DAR). According to their biochemical
and pharmacological properties, the receptors
can be divided into two subtype families: D1-
like receptor subfamily that includes the D1
and D5 receptors, and the D2-like receptor sub-
family comprising the D2, D3, and D4 recep-
tors.14 The turnover of extracellular DA involves
both degradation by two main enzymes: monoa-
mine oxidase and catechol-O-methyltransferase
and reuptake by DAT, all critical elements in
DA homeostasis.15,16
Dopaminergic neurotransmission plays a criti-
cal role in processes such as learning, memory,
motivation, reward, risk assessment and loco-
motion.17–19 Conditions that challenge DA bal-
ance may impair these functions. In the brain,
we can find higher content in production areas
like pars compacta of the substantia nigra (SN) and
the ventral tegmental area (VTA). From these,
dopaminergic pathways project to the nucleus
accumbens (NAc), the frontal cortex (FC), and
the striatum (Str).
Parkinson’s disease (PD) is a DA-related
pathology in which there is a state of low DA
levels in SN, characterized by several motor
coordination and involuntary movement disor-
ders. PD treatment is based on the use of DA
precursors such as Levodopa (L-DA) and DA
Acta Anaesthesiologica Scandinavica (2015)
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agonists. Importantly, several reports show that
the prolonged use of these drugs in PD patients
is related to an increase in compulsive gam-
bling/shopping/eating behavior, hypersexuality,
and hyperphagia disorders.20
Changes in brain DA content induce behav-
ioral modifications, but how does this knowl-
edge correlate with the anesthesia field?
Occupational addiction in anesthesia
Substance abuse in health professionals21 is a
known problem. The literature about this sub-
ject shows that occupational hazards do not
translate in an increase in mortality of anesthesi-
ologists compared either with other specialties
or general population22,23; however, there seem
to be an increased risk of substance abuse and
suicide.24,25
The pharmacokinetic of short-acting drugs
such as propofol, remifentanil, and volatile
anesthetics make them virtually impossible to
trace in routine testing, and unless the health
worker is caught consuming or stealing, only
testing all health workers for drugs of abuse
would give us the real picture.
The anesthesiologist faces professional chal-
lenges such as exposure to stressful situations
and work overload that can lead to isolation,
burnout,26 and depression.27 Physicians under
these conditions may, therefore, develop mal-
adaptative strategies that lead to substance
abuse.28 Stress is a known trigger of changes in
brain reward circuits29 that may enhance the
reinforcing properties of drugs. GA have phar-
macological similarities to drugs of abuse:
reports show characteristics of high psychologi-
cal dependence such as relapse, strong cravings,
and continuous auto-administration irrespective
of negative consequences.30 On the top of the
most misused drugs, we can find opioids and
intravenous anesthetics, benzodiazepines, and
lastly volatile anesthetics. There is also specula-
tion that environmental exposure to GA can
induce changes that in a certain way could lead
to the development of addictive traits.31 The fact
that healthcare professionals exposed to stressful
environments also have easy access to drugs
with abuse and misuse potential turn this issue
not an institutional problem but a public health
one.
May general anesthetics be involved in
development of addiction?
Several drugs used during anesthetic procedures
have a direct effect on the dopaminergic system.
The most well-known and studied substances
that induce DA changes and addiction are opi-
oids, but we will focus specifically on GA.
Acute exposure to most GA produces a mixture
of sensations described as feeling drunk, confu-
sion, sedation, and loss of concentration capac-
ity. It can also induce psychadelic-like effects
such as dissociation, hallucinations, and distor-
tions in perception of reality. Volatile anesthet-
ics are chemically similar to solvent agents often
used as recreational drugs and produce similar
behavioral effects.32,33 It is impossible to talk
about anesthetics and DA without recalling the
origins of anesthesia: the first two substances
used as anesthetics, nitrous oxide and ether,
were used recreationally even before being
introduced in medical practice as stated in his-
torical reports describing “laughing gas par-
ties”.34 In human studies,35–38 subanesthetic
doses of sevoflurane, nitrous oxide, propofol,
and ketamine all correlated with liking and
were rated as something the subject “will try
again”; they also produced dose-related rein-
forcement and abuse-related subjective effects.
Ketamine is a well-known club drug, and users
display riskier behavior.39 The effects of GA
exposure in behavior of animal models have
also been studied and correlates with behavioral
changes similar to drugs of abuse such as anxi-
ety and craving. Nitrous oxide is known to
induce anxiolysis in animal models, and the
effect is reversed by the benzodiazepine antago-
nist flumazenil.40 These reports suggest that
exposure to GA can induce addictive behaviors
both in animal models and in humans.
The impact of general anesthetics on brain
dopamine
As above mentioned, GA act in the whole brain:
they modify neuronal system, the release and
reuptake of neurotransmitters, and the way neu-
rons respond to them. The sum of all these
effects represents the behavioral endpoint of GA
action: loss of consciousness, immobility, and
amnesia. DA is believed to contribute to GA
Acta Anaesthesiologica Scandinavica (2015)
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effects as the amount of dopaminergic activity
influences the amount of GA needed to induce
anesthesia.41 On the other end, the depletion of
brain DA can induce a state of immobility.42
We will now make considerations on the
modulation of DA in brain by different anes-
thetic agents. Most of the data are based in
microdialysis studies where samples of brain
intersticial fluid are sampled during exposure to
GA alone or with DA modulators in transla-
tional research using rodent and primates.
Halotane
Exposure to halothane in high doses increases
extracellular DA levels in Str43–45 and potentiate
the dopaminergic action of other drugs.46,47 The
level of dopaminergic metabolites is also
increased indicating a higher turnover. The use
of lower anesthetic doses fail to increase DA
levels; however, DA metabolites still increase.
So, there seems to be a complex dose-related
response, but there is always some effect. In the
NAc, there is also an increase in DA.48 So evi-
dence show that halothane seems to induce DA
availability in areas that play an important role
in DA driven behavior.
Isoflurane
Isoflurane anesthesia also induces a dose-depen-
dent increase in Str DA49–51 with lower doses
failing to show changes in brain DA but pro-
ducing changes in metabolites.
Nitrous oxide
The use of this volatile NMDA antagonist
induced a slight DA increase in NAc and a
decrease or no effect in Str.52,53
Xenon
Use of xenon failed to change DA levels in NAc.
There are no works regarding other brain
areas.54
Ketamine
In animal models, the NMDA antagonist seems
to have almost no effect in DA levels when used
in low dosages, but higher subanesthetic and
anesthetic dosages increase DA in Str, NAc and
FC.55–58 This effect is also seen in human
in vivo imaging studies that report an increase
in striatal DA release after an acute challenge
with ketamine.59 But when the exposure is
repeated, there is a reduction in FC dopaminer-
gic function with impairment in working mem-
ory and executive functions.60
Pentobarbital
Pentobarbital induces decreases DA in the NAc,
producing a state of ataxia in rodents. It also
inhibits the effect of L-DOPA in extracellular
DA increase.50 Like other GAs, when given in
lower doses does not change DA levels.58
Propofol
Propofol at lower subanesthetic dosages
decreases DA NAc content while more clinically
relevant higher subanesthetic and anesthetic
dosages of propofol increase NAc DA levels.61
Propofol also has the ability to induce expres-
sion of DeltaFosB in NAc, a protein whose
expression is also increased by drugs of abuse.62
Additionally, propofol exposure decreases DA
levels in Str and in FC.63
Measurements of dopaminergic activity either
in DA production, degradation, and reuptake
can be used to assess dopaminergic pathways.
DA is degraded into 3,4-Dihydroxyphenylacetic
acid (DOPAC) and homovanillic acid (HVA). In
rodents, DOPAC is the major metabolite and
DOPAC accumulation provides an indicator of
dopaminergic neurons activity, while the
DOPAC:DA ratio is an indication of DA turn-
over. In Str, DA metabolite levels are increased
by halothane, isoflurane, sevoflurane, and prop-
ofol exposure.44–46,64 In the NAc, they are
increased after exposure to isoflurane,65 sevoflu-
rane, and propofol. In addition, DAT seems to
be inhibited by most GAs. In fact, studies show
that halothane, isoflurane, propofol, ketamine,
ethomidate, and thiopental inhibit specific
synaptosomal uptake of DA in a concentration-
dependent manner in rat brain.41,66,67 The over-
all effect of exposure to GA is a dose-dependent
increase in DA and its metabolites during acute
exposure.
Acta Anaesthesiologica Scandinavica (2015)
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What are the implications of changed DA levels
induced by GA?
We will now focus the effect of GA in brain
areas relevant to DA-driven behavior. Striatal
influence of GA seems to be “agent” and “dose-
specific”, but there is no doubt that GA have
an impact on Str DA release. The Str serves as
the entry point for cortical and thalamic inputs
into basal ganglia circuitry. The release of DA
in Str during reward learning tasks is known
to be an important modulator of acquisition of
habit or goal-directed tasks. Disorders that
affect DA such as PD, Huntington’s disease,
and substance abuse produce impairments in
these processes. Exposure to GA specifically
halothane, isoflurane, and ketamine have the
potential to impair those functions through
changes in Str DA.43–47,49–51,55
The NAc is believed to participate in many
functions that have been shown to be important
in reward learning tasks.68 Most drugs of abuse
are known to produce an increase in DA levels
at the NAc, in a manner similar to propofol, ke-
tamine, and halothane.48,52,57
Dopaminergic activity in the prefrontal cortex
(PFC) plays an important role in cognitive func-
tions. DA depletion in PFC impairs working
memory performance tasks in primates69,70 and
the use of DA agonists improves performance in
animals with poor working memory.71,72 Both
human and animal studies suggest that repeated
exposure to noncompetitive NMDA antagonists
reduces PFC dopaminergic function with
impairment in working memory and executive
function.73,74 We can speculate that while acute
exposure to GA with NMDA antagonist activity
induces increase in PFC DA, continuous expo-
sure is prone to decrease PFC DA and impair
working memory and executive function perfor-
mance which is the pattern found in chronic
users. Chronic exposure to GA, such as repeated
anesthetic procedures, theoretically can induce
the same changes. Such as stated earlier, there
are concerns of a similar mechanism responsible
for development of addiction in susceptible
individuals subjected to environmental expo-
sure.
To summarize, increase in DA metabolites
suggests that most GA induce higher DA levels
and turnover in several brain regions, especially
in the Str and in the NAc. Activation of these
particular areas is a hallmark pattern of several
drugs that induce addiction and impair DA dri-
ven behavior.
Conclusion
Review of the literature suggests that general
anesthesia modulates the dopaminergic path-
ways. Behavioral data both in human and ani-
mal models support the possible development
of an addictive trait in subjects exposed to GA.
Some of the molecular features of drugs of abuse
concerning DA are also found in GA such as DA
release and availability in areas such as NAc
and Str. It is likely that all behavior functions
that rely on dopaminergic transmission can be
potentially impaired after GA exposure.
Changes in reward system and memory forma-
tion potentially may impair cognitive abilities
such as reasoning, language comprehension,
planning, and spatial processing. Several clini-
cal trials show that surgery and anesthesia may
cause “postoperative cognitive dysfunction” and
changes in dopaminergic brain systems may
contribute to this phenomenon. However, we
still do not know how much it impacts on our
behavior. The potential to play with reward
mechanism, decision-making processes and cog-
nitive performance impose a need for judicious
use of GA. Further research is needed to answer
all these questions and provide both even better
standard of care to our patients and less occupa-
tional hazards to healthcare workers.
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ORIGINAL ARTICLE
The positive effect on ketamine as a priming adjuvant in
antidepressant treatment
Melo1,2, N Kokras3, C Dalla3, C Ferreira1,2, Ventura-, AP Silva1,2, N Sousa1,2 and JM Pêgo1,2
Ketamine is an anesthetic with antidepressant properties. The rapid and lasting effect of ketamine observed in preclinical and
clinical research makes it a promising therapeutic to improve current major depression (MD) treatment. Our work intended to
evaluate whether the combined use of classic antidepressants (imipramine or ⇥uoxetine) and ketamine would improve the
antidepressant response. Using an animal model of depressive-like behavior, we show that the addition of ketamine to
antidepressants anticipates the behavioral response and accelerates the neuroplastic events when compared with the use of
antidepressants alone. In conclusion, our results suggest the need for a reappraisal of the current pharmacological treatment of MD.
Translational Psychiatry (2015) 5, eœœ; doi:10.1038/tp.2015.66; published online xx xxx 2015
INTRODUCTION
Major depression (MD) is a highly incident and prevalent
multifactorial disease responsible for great personal and socio-
economic burden.1 Currently used therapeutic regimens have
important limitations such as long-time lag for clinical response,
induction of resistance or even response failure.2,3 Several
different factors seem to have a role in MD: imbalances in
neurotransmitters4 and cytokine production,5,6 hypothalamic–
pituitary–adrenal axis dysregulation7 and impaired
neuroplasticity.8,9
Currently used antidepressants target the metabolism/transport
of monoaminergic neurotransmitters, such as serotonine and
noradrenaline. However studies show that glutamate (GLU)
deregulation is also implicated in MD.10,11 The use of NMDA (N-
methyl-D-aspartate) receptor antagonists as antidepressants is a
relatively new concept.12 Ketamine (KET), an NMDA antagonist,
was observed to induce a rapid antidepressant action in MD
patients,13 even in those considered treatment resistant.14,15 The
rapid antidepressant effect of KET has also been described in
animal models of depressive-like behavior.16,17 Such an effective
drug promises to be an important therapeutic tool to improve MD
treatment ef cacy but, surprisingly, studies where classic anti-
depressants are used in combination with NMDA antagonists are
scarce. Therefore, herein we assessed whether the use of an acute
KET treatment could improve the ef cacy and/or anticipate the
clinical effect of both tricyclic antidepressants and selective
serotonin reuptake inhibitor agents in a rat model of depression.
MATERIALS AND METHODS
Animals
Male Wistar rats (Charles River Laboratories, Barcelona, Spain), aged
3 months were housed (three per cage) under standard laboratory
conditions (12 h light: 12 h dark cycle, at 22 °C, relative humidity of 55%;
free access to food and water). Eighty-four animals were used. Animals
initially performed the determination of the baseline value of sucrose
consumption test (SCT) and then were randomly assigned to the following
experimental groups—a control group without stress exposure and six
groups exposed to unpredictable chronic mild stress (uCMS). After 4 weeks
used to establish a depressive-like behavior phenotype, uCMS-exposed
animals were randomly assigned to six different groups: one untreated
group (i) uCMS, and the other  ve experimental groups according to the
assigned treatment: (ii) imipramine, (iii) ⇥uoxetine, (iv) KET alone for the
 rst 3 days and saline for the remainder period (uCMS-KET), or treated with
KET daily for 3 days and either (v) FLX (KET-FLX) or (vi) IMP (KET-IMP) for
the remaining treatment period (n =12 per group; Figure 1).
Behavioral tests were conducted during the diurnal phase, between
1000 and 1800 h. Animals were euthanized 24 h after performing the last
behavioral evaluation and brains processed for neurochemical and
structural analysis. All the procedures were carried out in accordance with
the Animal Ethics Committee of the Portuguese National Veterinary
Directorate and with the guidelines for the care and handling of laboratory
animals in the Directive 2010/63/EU of the European Parliament.
Unpredictable chronic mild stress
A modi ed version of an uCMS protocol18 was used to establish the animal
model of depressive-like behavior. It consisted of chronic exposure to
unpredictable mild stressors (con nement to a restricted space for 1 h,
placement in a tilted cage (30 °) for 3 h, housing on damp bedding for 8 h,
overnight illumination, 18 h food deprivation followed by exposure to
inaccessible food for 1 h, water deprivation for 18 h followed by exposure
to an empty bottle for 1 h, and reversed light/dark cycle for 48 h every
7 days) until establishment of the model phenotype and then through the
duration of behavioral evaluation.
Antidepressant treatment
After establishment of depressive-like behavior, uCMS animals were
treated according to the assigned group with daily intraperitoneal
injections of saline, FLX (10 mg kg✓ 1, Kemprotec, Cumbria, UK), IMP (10 -
mg kg✓ 1, Sigma-Aldrich, St. Louis, MO, USA) and KET (10mg kg ✓ 1, P zer)
with 0.9% saline as vehicle for 14 days and then performed behavioral
evaluation. Treatment and administration scheme were chosen on the
basis of their therapeutic effects in previous studies.8,19
KET is a general anesthetic with psychomimetic characteristics and has
been used to induce psychotic trait in animal models of schizophrenia. To
rule out that the dosage-induced phenotypic changes related no animal
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models of schizophrenia, we assessed locomotor activity in the open  eld
and sensorimotor gating in the PPI.
Behavioral analysis
All animals (controls and uCMS-exposed) were submitted to a series of
behavioral testing. Sucrose preference tests were performed weekly over
the 6 weeks of exposure to uCMS. The remainder tests (elevated-plus
maze, forced-swim test and open  eld) were performed after 14 days of
treatment (Figure 1).
Sucrose consumption test
Anhedonia was assessed weekly during exposure to uCMS using the SCT.
Brie⇥y, animals were allowed to habituate to the sucrose solution for
1 week before the uCMS protocol to establish baseline preference levels.
To test sucrose preference, animals that were food- and water-deprived for
18 h were presented with two pre-weighed bottles containing 1% sucrose
solution or tap water for a period of 1 h. Sucrose preference was calculated
according to the formula: sucrose preference= (sucrose intake/(sucrose
intake+water intake))◊ 100, as previously described.8 Anhedonia was
de ned as a reduction in sucrose preference.
Elevated-plus maze
To assess anxiety-like behavior, animals were tested on an elevated-plus
maze (MED-NIRPMNR; Med Associates, St Albans, VT, USA) as previously
described.20 Animals were placed in the central junction facing an open
arm, and allowed to explore for 5 min. Entry was de ned as all four paws
being positioned within one arm. The test was recorded and the ratio
between time in open arms and time in closed arms was measured.
Activity in the open arms was calculated as open arm entries percentage
(entries into the open arms/total entries into all arms) and time spent in
open arm percentage (time spent in the open arms/total time spent in all
arms). The degree of anxiety was indirectly related to the time spent in the
open arms and the number of open arm entries.
Forced-swim test
Learned helplessness was evaluated in the forced-swim test on the last day
of exposure to uCMS. Twenty-four hours after a pre-test session (10 min),
rats were placed in cylinders  lled with water (25 °C; depth 30 cm) for a
period of 5 min. Test sessions were assessed using a camera connected to
a video tracking system (Viewpoint, Lyon, France); the system automati-
cally calculated immobility time and latency to immobility. Learned
Figure 1. Diagram with experiment protocol. Complete experiment protocol (a); treatment period and behavioral evaluation (b). EPM,
elevated-plus maze; FST, forced-swim test; OF, open  eld; SPT, sucrose preference test; uCMS, unpredictable chronic mild stress.
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helplessness behavior was de ned as an increase in time of immobility and
a decrease in latency to immobility.
Open  eld
To assess locomotor activity, rats were placed in an open- eld apparatus
(43.2 (length)◊ 43.2 (width)◊ 30.5 (height) cm, transparent acrylic walls
and white ⇥oor, Med Associates) in a room illuminated by white light.
Instant position was monitored over a period of 5min by an array of two
16 beam infrared arrays. Total distance and average speed was used as a
measure of locomotor activity.
Pre-pulse inhibition
An additional setting of animals was used to evaluate KET safety regarding
induction of pre-pulse inhibition (PPI) impairment. Startle re⇥exes were
measured in two identical startle response systems (SR-LAB, San Diego
Instruments, San Diego, CA, USA), each consisting of a non-restrictive
Plexiglas cylinder ( 8.8 (internal diameter) cm, 22.2 (length) cm), mounted
on a Plexiglas platform and placed in a ventilated, sound-attenuated
chamber. Cylinder movements were detected and measured by a
piezoelectric element mounted under each cylinder. A dynamic calibration
system (San Diego Instruments) was used to ensure comparable startle
magnitudes across the two devices. Startle stimuli were presented through
a high frequency speaker located 33 cm above the startle chambers. Startle
magnitudes were sampled each millisecond (ms) during a period of 200
ms beginning at the onset of the startle stimulus. A startle response is
de ned as the peak response during this 200-ms period. Animals were
habituated to the apparatus 5min daily 2 days before the testing period.
After the habituation period, rats were taken from their home cage and
placed in the test chamber. The chamber was then sealed and each animal
allowed to acclimatize to the startle chamber for a period of 5min. In
addition, background white noise, with an intensity of 63 dB, was
maintained to minimize the impact of acoustic stimuli outside the
chamber environment. Following  ve introductory 120-dB startle trials
(noise lasting 40ms), a total of 35 test trials were pseudo-randomly
delivered as follows: (a)  ve trials with background noise only, (b) 10 startle
trials of 120 dB and (c)  ve pre-pulses of each of four different intensities
preceding a startle trial. Pre-pulse intensities of 2, 4, 8 and 16 dB above the
background noise level lasted 20ms and preceded the 120-dB startle
presentation in 100ms. Inter-trial intervals ranged from 10 to 20 s. The
average startle response (AVG) was assessed in the 100-ms period
following the onset of the startle stimulus presentation.
Neurochemical analysis
Monoamines levels were measured using high performance liquid
chromatography (HPLC), combined with electrochemical detection. From
each experimental group, seven rats were killed by decapitation. After
decapitation, the animal heads were snap-frozen in liquid nitrogen to
prevent tissue degradation. The brains were quickly extracted and placed
in an icy surface; under a stereomicroscope the prefrontal cortex (PFC),
dorsal hippocampus (DH), ventral hippocampus (VH) and nucleus
accumbens (NAc) were dissected. The dissected tissues were weighed
and then homogenized and deproteinized in 100 ºl of 0.2 N perchloric acid
solution (Applichem, Darmstadt, Germany) containing 7.9 mM Na2S2O5 and
91.3 mM Na2-EDTA (Riedel-de Haën AG, Seelze, Germany), centrifuged at
15 000 r.p.m. for 45min at 4 °C and the supernatant stored at ✓ 80 °C until
analysis.
The analytical measurements were performed using a GBC LC1150 (GBC,
Braeside, VIC, Australia) HPLC pump coupled with a BAS LC4C (Bioanalytical
Systems, West Lafayette, IN, USA) electrochemical detector and pre-column
derivatization as described previously.21 The working electrode was glassy
carbon, the reference electrode was Ag/AgCl and the columns used were
ODS Hypersil, 250mm◊ 4.6 mm, 5 ºm (Thermo Fisher Scienti c, Waltham,
MA, USA). The voltage of the working electrode was set at +800mV in the
LC4C amperometric detector and the ⇥ow rate of the LC1150 HPLC pump
was set at 1.0 ml min✓ 1. The mobile phase consisted of an acetonitrile
(Merck, New York City, NY, USA): 100mM phosphate buffer (5:95) pH 4.9,
containing 50 ºM Na2-EDTA (Riedel-de Haën). Samples were initially diluted
1:5 with ddH2O, then further diluted 1:1 with 0.1 M Borax buffer (Sigma-
Aldrich), pH 9.6. o-Phthalaldehyde (Sigma-Aldrich) was subsequently
added and left to react at room temperature for 10min before injection.
Quanti cation of glutamate and aspartate was done by comparison of the
area under the curve with that of reference external standards using HPLC
software (Clarity, Data-Apex, Prague, Czech Republic), as previously
described.22,23
Histological procedures
After the end of behavioral evaluation,  ve rats from each group were
perfused transcardially with saline (NaCl 0.9%) under deep pentobarbital
anesthesia. Brains were removed and kept in Golgi-Cox solution for
15 days and then transferred to a 30% sucrose solution for 5 days. Sections
(200 ºm) were obtained using a vibratome and collected in 6% sucrose
and blotted dry onto gelatin-coated microscope slides. They were
alkalinized in 18.7% ammonia, developed in Dektol (Kodak, Rochester,
NY, USA),  xed in Kodak Rapid Fix, dehydrated and xylene-cleared before
coverslipping. Dendritic arborization and spine numbers were analyzed in
layer II/III of infralimbic area of PFC, and dentate gyrus and CA3 region of
hippocampus. Selected neurons had every branch of the dendritic tree
reconstructed at ◊ 1000 (oil) magni cation using a motorized microscope
(Axioplan 2; Carl Zeiss, Jena, Germany) and Neurolucida software
(Microbright eld, Williston, VT, USA) and three-dimensional analysis of
the reconstructed neurons was performed using NeuroExplorer software
(Microbright eld). For each animal, 20 neurons were studied and
measurements from individual neurons from each animal were averaged.
The following dendritic morphology parameters were examined: dendritic
length and the number of primary dendrites and dendritic branching
points were compared across experimental groups; dendritic spines were
assessed according to their morphology mushroom-shaped, thin, thick and
rami ed spines and dendritic spine density (number of spines/dendritic
length) and the proportion of spines in each category was calculated for
each neuron in branches that were either parallel or at acute angles to the
coronal surface of the section. In dentate granule cells, proximal and distal
branches were analyzed for each neuron; basal branches and proximal and
distal apical branches in pyramidal neurons in the CA3 region and
infralimbic area of the PFC were analyzed. Neuronal reconstructions were
masked to the observer.
Statistical analysis
Sample size was determined considering a medium effect size (f = 0.25), a
type I error ±= 0.05 and a statistical power (1—type II error) of 0.8, and also
the performance of HPLC and golgi analysis after behavioral analysis, with
the need to establish two diferent groups of animals. In practice, we ended
up using a total of 84 animals, with n= 12 to each experimental group.
During the experiment, we performed three moments of randomization:
the  rst one after the establishment of a baseline in SCT, the second one
after establishment of the uCMS phenotype, and the last one after
behavioral evaluation to establish two separate groups to perform either
HPLC or neurostructural analysis.
We used masking of the experimental group assignment to all animal/
samples during performance and analysis of behavior tests, HPLC and
structural Golgi analysis.
Data obtained in experiment were analyzed applying analysis of
variance. Quantitative data obtained for parameters analyzed regarding
elevated-plus maze, forced-swim test, open  eld, PPI, neuronal dendritic
architecture and HPLC measurements were analyzed using one-way
analysis of variance, and whenever appropriate, post hoc comparisons
between experimental groups were performed using Bonferroni’s test. For
data obtained in the SCT, we used repeated measures analysis of variance.
Sphericity assumption and homogeneity of group variances were veri ed
and statistical analyses were made accordingly. During statistical analysis,
we did not perform any data transformation. All data are presented as
means± s.e.m. In all cases, statistical signi cance was set at P} 0.05 (two-
sided). Statistical analysis was performed using IBM SPSS statistics 20.0
(IBM Corporation, Armonk, NY, USA).
RESULTS
Behavioral data
To evaluate hedonic behavior, the SCT was performed weekly
during the establishment of the depressive-like behavior and
during the treatment period. After 4 weeks of exposure to uCMS,
animals developed a signi cant difference in sucrose preference
compared with control animals (Po0.05). On the seventh day of
treatment, animals treated with KET (Po0.05), FLX-KET (Po0.05)
and IMP-KET (Po0.05) animals (F6,77 = 4.179, Po0.01), but not the
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remaining treated groups had reversion of anhedonic phenotype
(Figure 2b). On the 14th day, all animals treated with antidepres-
sant display behavioral rescuing of anhedonic behavior (IMP
(Po0.01) and FLX (Po0.05), IMP-KET (Po0.001) and FLX-KET
(Po0.001)), except for those given only KET that did not display
any longer the behavioral rescuing effect detected 1 week before
(F6,77 = 10.50, Po0.001; Figure 2c). In animals given FLX, when KET
was added (FLX-KET) there was a signi cantly higher sucrose
preference at 14th day when compared with animals given FLX
alone (Figures 2a and c).
In the forced-swim test, uCMS animals showed decreased
latency to immobility time (F6,77 = 7.912, Po0.001) and increased
immobility time (F6,77 = 11.00, Po0.01) when compared with
control animals. Comparing with uCMS, all treated animals
showed a signi cantly increased latency to immobility: FLX, KET
(Po0.05), IMP (Po0.01) and IMP-KET, FLX-KET (Po0.001;
Figure 3a); and also a signi cant decrease in immobility time:
IMP, FLX (Po0.05) and IMP-KET, FLX-KET (Po0.01; Figure 3b). In
latency to immobility time, the addition of KET to those animals
treated as well with FLX induced a signi cant bene cial effect.
Figure 2. Ketamine effect in the reversion of anhedonic phenotype. Effect of uCMS in sucrose preference (a). Reversion of anhedonic
phenotype at the end of  rst week of treatment in KET, FLX-KET and IMP-KET (Po0.05) (b); Rescue of anhedonic behavior by the end of
second week of treatment in all animals treated with antidepressant and the addition of KET produces a signi cantly higher sucrose
preference by the end of the second week when comparing the group FLX-KET with FLX (Po0.05) (c). uCMS, umpredictable chronic mild
stress; FLX, ⇥uoxetine; IMP, imipramine; KET, ketamine; (mean± s.e.m., n= 12, *Po0.05; **Po0.01; ***Po0.001).
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In the elevated-plus maze test, uCMS animals displayed an
anxious phenotype, spending signi cantly less time exploring
open arms than control animals (F6,77 = 3.111, Po0.001); both
IMP-KET (Po0.05) and FLX-KET (Po0.01) groups showed a
signi cant increase in time spent in open arms when compared
with uCMS animals; no other signi cant differences were found
(Figure 3c). Regarding the number of entries in open arms, control
animals showed a signi cantly higher number than untreated
uCMS group (F6,77 = 11.05, Po0.001) and both FLX (Po0.01) and
IMP-KET, FLX-KET (both Po0.001) also have signi cantly higher
entries in open arms (Figure 3d).
No signi cant effects of uCMS or pharmacologic treatment were
found concerning locomotory activity, as evaluated in the open-
 eld test (data not shown). Treatment with KET, in the dosage
used in our experimental protocol, failed to show PPI disruption
(data not shown).
Neurotransmitter pro le
In MD, therapy is still largely based on the ‘monoaminergic
hypothesis’, which is fundamentally associated with alterations in
the level of neurotransmitters. According to this and as an attempt
to investigate the possible mechanism underlying the effect of
giving KET together with antidepressants, the levels of neuro-
transmitters, more speci cally GLU and aspartate (ASP) were
analyzed by HPLC. For that, important key areas for MD such as
PFC and hippocampus were selected. In addition, we have
investigated the levels of these neurotransmitters in additional
brain areas, which are related to the behavioral pro le of recovery,
such as the NAc. (Figure 4).
Taking into consideration the GLU levels, NAc was the only
stress-induced brain region that displayed a reduction in its levels
(F6,55 = 2.254, Po0.01). Treatment with antidepressants produced
an increase in GLU levels, but only IMP-KET and FLX-KET displayed
a signi cant increase in GLU levels compared with untreated
animals (both Po0.01; Figure 4a).
Measurement of ASP levels showed no overall effect in PFC
(F6,55 = 0.672, P=0.673; Figure 4f), DH (F6,55 = 1.397, P=0.234;
Figure 4g) and VH (F6,55 = 1.143, P=0.325; Figure 4h). Contrarily, in
the NAc brain area, there was an overall group effect (F6,55 = 2.554,
P=0.031); post hoc analysis showed control animals have higher
ASP than uCMS untreated animals (F6,55 = 2.261, Po0.05) and that
uCMS-exposed animals treated with IMP-KET and FLX-KET have
signi cantly higher ASP levels than untreated uCMS animals
(F6,55 = 2.261, Po 0.05; Figure 4f).
Neuronal structural analysis
Given the neuroplastic action of antidepressants, we thought it to
be interesting to analyze dendritic architecture of neurons in these
areas. There is evidence that KET can induce rapid changes in
dendritic spine morphology, which may be relevant to the
antidepressant effect shown in the behavioral analysis. We focus
our attention in neurons from layers II/III of infralimbic (IL) cortex
in PFC, pyramidal neurons from CA3 and granule neurons from
the hippocampus and medium spiny neurons from NAc.
Figure 3. Ketamine treatment effect in anxiety and learned helplessness. All treated animals showed a signi cantly increased latency to
immobility: FLX, KET(Po0.05), IMP, (Po0.01) and IMP-KET, FLX-KET (Po0.001). The addition of KET caused a signi cant increase in latency to
immobility time in FLX-KET against KET (a); signi cant decrease in immobility time: IMP, FLX (Po0.05) and IMP-KET, FLX-KET (Po0.01) (b); IMP-
KET (Po0.05) and FLX-KET (Po0.01) groups with signi cant increase in time spent in open arms when compared with uCMS animals (c); FLX
(Po0.005), IMP-KET (Po0.001) and FLX-KET (Po0.001) with signi cant higher entries in open arms (d). FLX, ⇥uoxetine; IMP, imipramine; KET,
ketamine; uCMS, unpredictable chronic mild stress; (mean± s.e.m., n= 12, *Po0.05; **Po0.01; ***Po0.001).
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In the pyramidal neurons of the IL, uCMS induced atrophy in
basal and apical dendrites (F6,28 = 8.563, Po0.001; F6,28 = 4.074,
Po0.01). In basal dendrites, treatment with IMP-KET (Po0.01),
FLX (Po0.05) and FLX-KET (Po0.001) induced a reversion of
dendritic shortening. In the apical dendrites, all treated animals
(Po0.05) had a signi cant recovery (Figures 5g and d).
In dentate gyrus granule cell dendrites, data con rm a
signi cant stress-induced atrophy (F6,28 = 7.103, Po0.05), which
Figure 4. Ketamine treatment induces changes in HPLC measured levels of (a–d) glutamate (GLU) and (e–h) aspartate. IMP-KET and FLX-KET
increase in GLU levels compared with untreated animals in NAc (both Po0.01) (a). Treatment in IMP-KET and FLX-KET increases aspartate
levels in PFC (Po 0.05) (f). FLX, ⇥uoxetine; IMP, imipramine; KET, ketamine; NAc, nucleus accumbens; PFC, prefrontal cortex; (mean ± s.e.m.,
n= 7, *Po0.05; ***Po0.001).
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was recovered by the treatment with IMP-KET (Po0.001), IMP and
FLX-KET (both Po0.05). Animals treated with KET alone and FLX
alone did not show signi cant changes in dendritic length
(Figure 5j).
Hippocampal CA3 pyramidal neurons basal (F6,28 = 33.28,
Po0.001) and apical (F6,28 = 17.93, Po0.01) dendrites show a
signi cant decrease in their length in animals that were exposed
to uCMS. Treatment with KET (Po0.001), IMP-KET (Po0.001) and
FLX-KET (Po0.001) recovered basal dendritic length, whereas
Ketamine as a priming adjuvant in antidepressant treatment
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FLX-KET was able to induce a signi cant increase in basal dendritic
length compared with FLX alone (Po0.01). Neither IMP nor FLX
alone increased CA3 basal dendritic length signi cantly when
compared with uCMS animals. Regarding the apical dendritic tree,
treatment with KET (Po0.01), IMP-KET (Po0.01), FLX alone
(Po0.01) and FLX-KET (Po0.01) induced recovery, whereas
treatment with IMP alone failed to increase CA3 apical dendritic
length signi cantly. Both IMP-KET and FLX-KET promoted a higher
regrowth than IMP (P40.001) and FLX (P40.001; Figures 5m and
p). Exposure to uCMS induced an increase in dendritic length in
NAc medium spiny neurons (F6,28 = 24.73 Po0.001), and this
feature was reversed within all treatment groups (all Po0.01,
Figure 5a).
A signi cant decrease in spine density (SD) was found in basal
(F6,28 = 22.11, Po0.001) and apical (F6,28 = 6.86, Po0.05) IL
dendrites of uCMS animals. Treatments with KET (Po0.001), IMP
(Po0.001), IMP-KET (Po0.001), FLX (Po0.001) and FLX-KET
(Po0.001) increased SD in IL basal dendrites; FLX-KET signi cantly
increased SD in basal dendrites when compared with FLX alone
(F1,28 = 6.86, Po0.05). Treatment with FLX (Po0.001) and FLX-KET
(Po0.001) increased SD in apical dendrites. No signi cant
increase of SD in apical dendrites was found in animals treated
with KET or IMP alone and in animals treated with IMP-KET.
Regarding spine morphology, mushroom spines are decreased in
uCMS animals both in apical (F6,28 = 5.712, Po0.001) and basal
(F6,28 = 2.668, Po0.001) dendrites when compared with control
animals. Treatment with KET (Po0.001), IMP-KET (Po0.001) and
FLX-KET (Po0.001) reverted this pattern in basal and apical IL
dendrites. No signi cant increase in mushroom spine population
was found in animals treated with IMP or FLX alone; although the
treatment with IMP-KET and FLX-KET caused a signi cant rise in
mushroom spine population in apical and basal dendrites when
compared with IMP (Po0.05) and FLX (Po0.01) alone (Figures 5e,
f, h and i).
Hippocampal dentate gyrus neurons in uCMS untreated animals
have signi cant lower dendritic SD (F6,28 = 7.613, Po0.05) when
compared with control animals. Treatment with FLX (Po0.01) and
FLX-KET (Po0.01) signi cantly increased SD. There was no
signi cant increase in SD in animals treated with KET or IMP
alone or with IMP-KET. When evaluating the spine morphology,
speci cally the more developed mushroom spines, uCMS animals
present also less number of mushroom dendritic spines in dentate
gyrus neurons (F6,28 = 8,162, Po0.05) (t=5.267, Po0.001) but
treatment with KET (t=5.477, Po0.001), IMP (t=4.339, Po0.01),
IMP-KET (t=5.903, Po0.001), FLX (t=4.205, Po0.01) and FLX-KET
(t=5.359, Po0.001) restored mushroom spines numbers (Figures
5k and l).
In the CA3, neurons from uCMS animals displayed a signi cantly
lower dendritic SD in apical (F6,28 = 73.57, Po0.001) and basal
(F1,28 = 22.12, Po0.001) dendrites, which were recovered upon
treatment with all the tested drugs (Po0.001 to all). Addition of
KET to FLX treatment statistically increases spine density
(F1,28 = 6.86, Po0.05) in apical dendritic tree. The population of
mushroom dendritic spines is decreased in untreated uCMS
animals both in apical (F6,28 = 23.86, Po0.001) and basal
(F6,28 = 6.882, Po0.01) CA3 dendrites. In apical dendrites, treat-
ment with KET (Po0.001), IMP (Po0.05), IMP-KET (Po0.001) and
FLX-KET (Po0.001) caused an increase in mushroom spine
population. Both IMP-KET (Po0.01) and FLX-KET (Po0.001)
induce higher mushroom dendritic spine population. In basal
dendrites, treatment with KET (Po0.01), IMP-KET (Po0.01) and
FLX-KET (Po0.01) increased the amount of mushroom spines
(Figures 5n, o, q and r).
Exposure to uCMS induced a signi cant increase in SD in
medium spiny neurons of the NAc (F6,28 = 7.297, Po0.01) and this
feature was reversed in the treatment with IMP, IMP-KET, FLX-KET
(Po0.01) and FLX (Po0.05). Regarding spine morphology, uCMS
promoted a decrease in the population of mushroom spines
(F6,28 = 9.094, Po0.001) and all treatments signi cantly increase
mushroom spine compared with the untreated uCMS animals
(Po0.001). Importantly, the animals treated with antidepressant
and ketamine (IMP-KET and FLX-KET) presented a signi cant
increase of mushroom spine population when compared with
those who were only given antidepressant (IMP or KET; Figures 5b
and c).
DISCUSSION
The use of KET in subanesthetic dose with antidepressant effect is
described both in animal models of stress and in MD
patients.13,24,25 Classic antidepressants are used with success in
our animal model, the uCMS.26 In our study, we aim to test the
effect of KET on the response of classic antidepressants. The effect
of KET alone is described in the literature, although there is a lack
of understanding regarding the synergetic effect of initial
antidepressant treatment with KET. Therefore, we propose to
investigate the effect of KET on the response of classic
antidepressants. In the literature, the methodology described for
the administration of ketamine is very heterogeneous; it goes
from single to multiple doses, the latest one given either daily or
in intermittent days. When designing the protocol of antidepres-
sant treatment we decided to use a multiple continuous method
with a short duration (3 days).
The SCT was used as a behavioral hallmark for recovery from
depressed phenotype. The  rst evaluation occurred at the seventh
day of treatment and indicated that only animals treated with KET
(either alone or in combination with other antidepressant) display
behavioral rescue of anhedonia. After one additional week of
Figure 5. Addiction of ketamine induces changes in neuronal dendritic morphology. In NAc medium spiny neurons: all treatment groups
restored decreased dendritic length (all Po0.01) (a); increase in SD in IMP, IMP-KET, FLX-KET (Po0.01) and FLX (Po0.05) treatment groups (b);
increase of MS population (IMP-KET and FLX-KET) compared with the animals given only antidepressant (IMP and KET) (c). IL apical dendrites
recover from decreased dendritic length (d). In IL apical dendrites, FLX (Po0.001) and FLX-KET (Po0.001) increased (e). IL basal dendrites,
treatment with IMP-KET (Po0.01), IMP (Po0,05) and FLX-KET (Po0,001) induced a reversion of dendritic shortening (g). In IL basal dendrites,
FLX-KET increased SD over FLX alone (h). Both IMP-KET and FLX-KET have increase in MS population in apical and basal dendrites when
compared with IMP (Po0.05) and FLX (Po0.01) alone (f and i). In DG hippocampal neurons: IMP-KET (Po0.001), IMP and FLX-KET (both
Po0.05) reverse the shortening in DG dendritic length (j); FLX and FLX-KET (Po0.001) increased SD (k); KET (Po0.001), IMP (Po0.01), IMP-
KET (Po0.001), FLX (Po0.01) and FLX-KET (Po0.001) restored MS (l). In hippocampal CA3 pyramidal neurons: KET (Po0.001), IMP-KET
(Po0.001) and FLX-KET (Po0.001) recovered basal dendritic length and FLX-KET produced increase in basal dendritic length compared with
FLX alone (Po0.01) (p); KET (Po0.05), IMP-KET (Po0.001), FLX (Po0.05) and FLX-KET (Po0.001) induced recovery in apical dendrites, both
IMP-KET and FLX-KET promoted a higher regrowth than IMP (P40.001) and FLX (P40.001) (m). Addition of KET to FLX treatment increases SD
(Po0.001) in apical dendritic tree (n) and KET (Po0.01), IMP-KET (Po0.01) and FLX-KET (Po0.01) increased the amount of MS (o); In CA3
basal dendrites all treated groups had a increase in SD (q); treatment with KET (Po0.001), IMP-KET (Po0.001) and FLX-KET (Po0.001)
produced an increase in MS and IMP-KET (Po0.01) and FLX-KET (Po0.001) induce higher MS population than IMP and FLX (r). DG, dentate
gyrus; FLX, ⇥uoxetine; IMP, imipramine; KET, ketamine; MS, mushroom spine; NAc: nucleus accumbens; SD, spinal density; (mean ± s.e.m., n= 5,
*Po0.05; **Po0.01; ***Po0.001).
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treatment, at the 14th day, all treated groups show reversion of
anhedonia, except the one only treated with KET, which showed a
reversion of the positive behavioral effect. In our results, we can
see the speci c effect of the interaction of KET added to
antidepressant treatment on the results of the treated group
KET-FLX. The effect of KET alone in anhedonia does not last until
the 14th day, but when given with FLX, it enhances it.
The second hallmark of this model is learned helplessness, a
measure of behavior despair. There was an increase in latency to
immobility time in all treated animals but the analysis of total
immobility time shows that the effect of KET alone is not detected
2 weeks after being administrated. Again, when KET is given with
FLX, it is evident that there is an increase in latency time
compared with the antidepressant alone.
The analysis of anhedonia and despair in our model showed
that combining KET with other treatments seems to anticipate the
increase in sucrose preference and to improve the response. KET
possibly is acting as an initial booster and keeps the antidepres-
sant response. However, when given alone it failed to show a
robust result.
We also assessed anxiety and show that the combination of KET
with FLX or IMP was able to signi cantly reverse the anxiety trait.
Again, there seems to be no anxiolytic effect after 2 weeks of KET
given alone. Some literature reports long-lasting anxyolitic effect
of KET given in a single dose to patients with depressive
disorders27 and in animal models when given in multiple
doses.28 However, we observed a positive effect when given with
antidepressants. When given together with the antidepressants,
bene cial effect of KET extends beyond the mood domain and
also potentiates the anxiolytic effects of SSRIs and tricyclic
antidepressant drugs.
The positive effect of initial dual therapy with KET and other
antidepressant, concerning behavioral recovery in our animal
model, is a faster initial increase in sucrose preference and a more
robust response after 2 weeks of treatment not only in anhedonia
but also in behavioral despair and anxiety.
MD disorder and stress disorders have been associated with
impaired functional connectivity,29,30 as a result of dysfunction
occurring by several pathways. To evaluate the impact of KET in
neurotransmission, we have analyzed the levels of both GLU and
also we evaluated the dendritic architecture. We assessed the
levels of GLU in regions relevant for depressive-like behavior. Our
major  nding was that NAc, a brain region implicated in
anhedonia,26,31 was the only region where KET, in association
with other antidepressants, triggered an increase in the levels of
GLU and ASP suggesting that this particular effect is ascribed to
glutamate metabolism. The failure to observe signi cant changes
in GLU or ASP levels in other brain regions probably relates to
temporal dynamics of the experimental design. However,
literature reports that both acute stressors and chronic stressors
increase basal release and increased presynaptic reuptake of GLU,
but most measurements were performed using mycrodialysis or
synaptossomal analysis, thus re⇥ecting extracellular contents, not
the overall content of GLU. There is evidence that KET acts as a
noncompetitive and nonselective high-af nity NMDA antagonist
also on GABAergic neurons and may rapidly increase GLU release,
for example, in the PFC.32,33 Although there is clinical evidence
that treatment for depression increases the release of glutamate in
the NAc,34 other studies using ketamine in individuals with MD
were not consistent in showing an association between therapy
and changes in neurotransmitter content.35,36 Present data
suggest changes in glutamatergic transmission, particularly in
the NAc, a mechanism through which KET helps restore mood.
Through the analysis of neuronal architecture, we con rmed the
impact of uCMS on shrinkage of dendritic arborizations in the
hippocampus and in the IL area of the PFC, and dendritic
hypertrophy in NAc medium spiny neurons.7,8,26,37 Globally,
groups treated with antidepressant and KET showed a recovery
of the morphology of their dendritic trees, with a more consistent
response in FLX than IMP. Yet, the most striking changes were
noticed in dendritic spines; we not only found that the addition of
KET to the antidepressant treatment boosted a signi cant
recovery in spine density when compared with antidepressants
alone, but also with greater spine maturation. KET is known to
have effects in synaptic plasticity: the fast-acting antidepressant
action of KET is known to be dependent on rapid protein synthesis
(namely of BDNF, PSD-95, GLuR1 and synapsin 1) and activation of
intracellular pathways such as mTOR, all of them physiologically
relevant for synaptic plasticity mechanisms, neuronal growth,
differentiation and synaptogenesis.38–41 Although the speci c role
of mTOR in NAc is not fully understood in depression, the effect of
mTOR modulation is well studied in addiction. Therefore, we can
speculate the existence of some similarity between addiction
development and in antidepressant action. Indeed, the use of
rapamycin not only blocks establishment of addiction, but also the
antidepressant effect of KET.42 The acute and lasting effect of KET
in neuronal remodeling might be one of the reasons why it
improves behavioral markers of recovery in our experiment. The
particular case of combined treatment in increasing more mature
dendritic spine population shows that processes related to
synaptic functioning and rewiring have an important role in
behavioral recovery.
In summary, the present data show that KET has the potential to
improve the action of classic antidepressants in brain regions
affected by uCMS, a validated animal model of depression. The
addition of KET to antidepressants accelerate recovery from
anhedonia. The speci c addition to FLX improves not only
anhedonia but also behavioral despair. Despite lack of robustness
in neurochemical data, we show improvement of glutamatergic
pro le in an area related to anhedonic behavior. The effects in
neuronal morphology show a potential mechanism for improve-
ment in synaptic connectivity in brain areas known to be affected
and responsible for behavioral hallmarks in MD. These results
show that KET has potential to improve the initial response of MD
treatment.
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Testing impulsive behavior in rodents is challenging and labor-intensive. We developed a
new behavioral paradigm—the Variable Delay-to-Signal (VDS) test—that provides rapid and
simultaneous assessment of response and decision impulsivity in rodents. Presentation
of a light at variable delays signals the permission for action (nose poke) contingent
with a reward. 2 blocks of 25 trials at 3 s delay flank a block of 70 trials in which light
is presented with randomly selected 6 or 12 s delays. Exposure to such large delays
boosts the rate of premature responses when the delay drops to 3 s in the final block,
an effect that is blunted by an acute methamphetamine challenge and that correlates with
the delay-discounting (DD) paradigm (choice impulsivity). Finally, as expected, treatment
with the NMDA antagonist MK-801 caused a generalized response increase in all VDS
blocks. The pharmacological validation, particularly with methamphetamine which has a
well established dual effect on response and decision impulsivity, and the correlations
between the impulsive behavior in the DD and VDS paradigms, suggests that the later is
able to provide, in a single session, a multi-dimensional assessment of impulsive behavior.
Keywords: rodent behavior, decision impulsivity, response impulsivity, delay-discounting, 5-csrtt,
methamphetamine, MK-801
INTRODUCTION
Impulsivity is defined as a tendency to act prematurely with-
out foresight (Dalley et al., 2011). It is a non-unitary construct
embracing impulsive response and impulsive choice (Evenden,
1999b; Winstanley et al., 2006; Dalley et al., 2011; Dalley and
Roiser, 2012). This multifactorial trait depends on a complex
morphophysiology involving multiple brain areas and neuro-
transmitter systems (Dalley et al., 2011; Dalley and Roiser, 2012).
Impulsivity is part of the normal behavioral repertoire, but, when
out of the normal range, can result in a disruptive behavior,
encountered in several psychiatric disorders including obsessive-
compulsive disorder (OCD), attention deficit/hyperactivity dis-
order (ADHD), mania, substance abuse, and schizophrenia
(Evenden, 1999a,b; Moeller et al., 2001).
Impulsive behavior is also present in rodents, both in normal
conditions and in models of psychiatric disease (Adriani et al.,
2003; Huskinson et al., 2012; Pattij and De Vries, 2013). It has
been assessed in a number of paradigms that are well estab-
lished in terms of their face, construct and predictive validity,
with the go/no-go (Harrison et al., 1999), the stop-signal reac-
tion task (SSRT; Eagle et al., 2008), the 5-choice serial reaction
time task (5-csrtt; Carli et al., 1983) and the delay-discounting
(DD; Evenden and Ryan, 1996) among the most used (for review
see Winstanley et al., 2006; Dalley and Roiser, 2012). The con-
struct of each of these paradigms varies substantially, reflecting
the non-unitary characteristic of impulsivity (Winstanley et al.,
2010; Dalley et al., 2011; Dalley and Roiser, 2012). In the first
three paradigms, impulsive responses result from an inability to
refrain from an action either when waiting for a go signal or in
the presence of an explicit no-go signal, reflecting what is con-
sidered “response impulsivity.” In contrast, in the DD, impulsive
responses are the result of a deliberate choice between a maximal,
though delayed, and an immediate but small, reward, reflect-
ing a so-called “decision impulsivity”. Although these paradigms
have provided valuable tools to study impulsivity in rodents, they
present several limitations including the extensive time commit-
ments (spanning over 2 months in some cases), the possibility
of confounding by factors like attention and reward valuation,
the acquisition of repetitive behaviors (accommodation) due to
the sequential performance of the paradigms and the mono-
dimensionality of the construct assessed in each test, that limits
the behavioral readouts to a single type of impulsivity.
In order to circumvent some of these problems, we developed
a new behavioral paradigm, the Variable Delay-to-Signal (VDS)
test, consisting of a series of trials, in a single 30min session, in
which the time period (60 s) where an action (nose poke) triggers
the delivery of a sugared reward is signaled by a light, presented
after a variable delay; a block of 3 s delay trials is followed by a
block with large and variable delays (randomized between 6 and
12 s) before a final block again with a 3 s delay. Rats learn the oper-
ant sequence (nose poke/reward) rapidly (after a few trials) and
the entire protocol lasts for 10 days, a significant reduction com-
paring to previously described paradigms. In addition, we have
validated the VDS by employing two drugs with well-established
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actions on impulsive behavior, methamphetamine and MK-801,
and by comparing the individual performance against two refer-
ence paradigms, 5-csrtt (response impulsivity) and DD (decision
impulsivity). Given the observed dual pro- and anti-impulsivity
action of methamphetamine (Hayton et al., 2012) in different
components of the VDS and their correlations with the refer-
ence paradigms, we suggest that the VDS provides an effective
assessment of both response and decision impulsivity.
MATERIALS AND METHODS
ORGANIZATION OF THE EXPERIMENTAL PROCEDURES
Three months old, male Wistar Han rats (Charles River
Laboratories, Barcelona, Spain) were used in all experiments.
Animals were kept in a room with controlled temperature (22 ±
1◦C), 12 h light/dark cycle (lights on at 8 a.m.) and housed in
pairs in plastic cages with food and water available ad libitum. The
dietary regimen was restricted to 1 h of food availability (19:00–
20:00) 3 days before the initiation of the behavioral experiments.
Body weight was thereon controlled to ensure that it did not
go below 85% of the initial value. All procedures involving ani-
mals were approved by local authorities and the experiments were
performed according to the guidelines of European Community
Council Directive 2010/63/EU.
We conducted two independent experiments (Figure 1A):
in the first, 20 animals sequentially performed the VDS
FIGURE 1 | General organization of the validation experiments and
operational diagrams of the VDS and preceding training protocol. (A)
In experiment 1, two VDS protocols were performed in the same group of
animals to test for methamphetamine and MK-801 effects on impulsivity,
followed by the 5-csrtt performed in drug-free conditions during the whole
protocol. In experiment 2, VDS was followed by DD. Each bar represents a
session, except for 5-csrtt and DD whose protocol extension varied
between individuals. (B) The VDS consisted in two parts: the training
protocol (10 sessions) and the VDS proper (1 session); while in the first the
delay-to-signal was fixed (3 s) and pre-signal nose pokes were punished
(TO), in the VDS proper, 2 blocks of 25 trials at 3 s delay were interposed by
a block of 70 trials at 6 and 12 s, pre-signal responses were registered but
not punished with a TO. In both training and VDS the signal duration was
set to a maximum of 60 s; the absence of a response within this period
was registered as an omission. 5-csrtt—5 choice serial reaction time task;
DD—delay discounting; TO—timeout; VDS—variable delay-to-signal task.
under methamphetamine/vehicle (VDS 1), the VDS under MK-
801/vehicle (VDS2) and the 5-csrtt; in the second, 12 animals
without any treatment performed the VDS (VDS3) followed by
the DD. In both the VDS1 and VDS2, animals were assigned to
receive either drug or vehicle according to their performance in
the preceding training sessions, so that both groups had a sim-
ilar mean prematurity score; in addition, in VDS2 both vehicle
and MK-801 groups had a similar number of animals previously
treated with methamphetamine. In VDS 1 session two animals
(one from each group) have not finished the task probably due to
a failure in the reward delivery system; these were excluded from
further analyses.
DRUGS
Methamphetamine was used in VDS 1 session to lessen impul-
sive behavior. A dose of 1mg/Kg of the racemic mixture (effective
dose of 0.5mg/Kg) was administered intraperitoneally in a freshly
prepared solution at a concentration of 1mg/mL (in saline)
30min before the initiation of the session (Hayton et al., 2012).
Methamphetamine hydrochloride was synthesized by an adap-
tation of a previously described method (Milhazes et al., 2007).
The NMDA antagonist MK-801 was used in VDS 2 session to
boost impulsive behavior. A dose of 0.03mg/Kg was administered
intraperitoneally in a freshly prepared solution at a concentra-
tion of 0.03mg/mL (in saline) 10min before the initiation of
the session (Fletcher et al., 2011). MK-801 was obtained from
Calbiochem (CA, USA, Catalog Number: 475878-10MG).
VARIABLE DELAY-TO-SIGNAL
The VDS task was performed in square operant chambers (OC;
25× 25cm; TSE Systems, Germany) having on a curved wall 5
squared apertures (2.5 cm) elevated 2 cm from the grid floor and,
in the opposite wall, a similar aperture (food magazine) con-
nected to a pellet dispenser. Each aperture contained a 3W lamp
bulb and an infrared beam system to detect the activity of the ani-
mal. Three 5-hole OCs, placed within sound attenuating boxes
with individual electrical fans for ventilation and white noise
production, were simultaneously used in our studies.
Animals were habituated to the testing conditions in 4, twice
daily (am/pm) sessions, 5h apart. In the first 2 sessions, animals
were placed in the OC for 15min with all lights off, access to
apertures 1–5 blocked by metallic caps and 10–15 sugared pel-
lets (45mg, Bioserv Inc., New Jersey, EUA) available in the food
magazine. In sessions 3–4, animals were placed in the OCs for
30min, all lights were on and animals had free pellets available
in the center nose poke aperture (response aperture, 2–3) and
the food-magazine (10–15). The protocol for VDS was initiated
the following day and included two phases, i. training and ii. test
(Figure 1B).
i. Training Sessions were initiated by turning on the house light
and delivering one sugared pellet in the food magazine, the
collection of which started an intertrial interval (ITI) of 3 s to
allow the animal to ingest it. Trials then started, consisting of
a 3 s period with only the house light on (delay period), fol-
lowed by lightning of the response aperture for 60 s (response
period). Nose pokes in this aperture were either punished
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 154 | 2
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with a timeout (TO) period in complete darkness (5 S), if
performed during the delay period (premature responses), or
rewarded with the delivery of a pellet if performed during the
response period. Collection of a food reward always triggered
a 3 s ITI, before a new trial begun. Except for the TO periods,
the house light was always on. Each session comprised 100 tri-
als to be performed in amaximumof 30min. Training sessions
occurred twice daily, with a 5 h interval in between, for 5 con-
secutive days. The average number of premature responses of
the overall group stabilized at ∼30% in the last 4 sessions of
training.
ii. Test The VDS testing session occurred on a single day and con-
sisted of 120 trials, similar to those previously described, with
the exception of the delay, which was 3 s in the first and the
last 25 trials and randomly either 6 or 12 s in the middle 70
trials (leading to a 3 s – 6/12 s – 3 s configuration), and, impor-
tantly, the fact that multiple nose pokes were allowed during
the delay period, i.e., premature responses did not initiate TO
punishment periods. (Figure 1B).
5-CHOICE SERIAL REACTION TIME TASK
The 5-csrtt was performed in the same apparatus as the VDS, fol-
lowing the general principles originally described by (Carli et al.,
1983). Briefly, each session started with the delivery of one pel-
let. Its collection by the animal initiated the first trial. At this
point the house light is on signaling an ongoing trial. After an
ITI of 5 s one of the five lights in the rear panel was illuminated
for a period of 60 S. Nose pokes in this aperture during the light
period or in the subsequent 5 s were rewarded with one pellet in
the food aperture whose collection marks the beginning of an
ITI that precedes a new light signal. Nose pokes in any of the
other 4 apertures initiated a time-out period of 5 s in darkness
after which a new trial is started (house light on). Each session
consisted in a sequence of 100 trials (or a maximum of 30min)
performed twice a day during the morning/afternoon periods.
The performance of the subjects was assessed using the following
experimental parameters:
• Accuracy—ratio of correct/total number of responses.
• Prematurity—responses during the ITI in any of the five
apertures (triggers a TO).
• Omissions—absence of response in appropriate time.
Other parameters including latency-to-feed and response delay
were also registered. Throughout the sessions the level of diffi-
culty was increased by decreasing the stimulus duration from 60
to 30, 10, 2, and 0.5 S. An accuracy ≥80% and omissions ≤20%
in two successive sessions were considered as criteria for level
change. The last level was performed during 15 sessions. The 5-
csrtt was initiated 2 days after the last session of the VDS; no
training preceded the sessions.
DELAY-DISCOUNTING
The DD task was performed in (OCs; 30.5 cm L × 24.1 cm W ×
21.0H) equippedwith two retractable levers located on either side
of a food magazine and a house light placed in the opposite side
(MEDAssociates). Information regarding animals’ activity within
the OC was registered with MED-PC IV software. Two chambers
were used each placed within an individual sound attenuating
cubicle. In the first 2 days, animals were placed in the OCs for
5min with the house light on and both levers retracted. In the
food magazine 3–5 pellets were made available. From days 3–5 a
continuous reinforcement protocol (CRF) was applied. A single
lever was made available and a sugared pellet was delivered for
each lever press. Sessions were terminated when 50 pellets were
obtained or if 30min had elapsed and were immediately followed
by a similar session differing only in the fact that the levers were
switched. The lever presentation order was counterbalanced over
days 3–5. The second step of the training protocol consisted in 3
sessions (1 per day; days 6–8) onwhich the animal was required to
nose poke the food magazine in order to trigger the lever presen-
tation and initiate the trial when the house light was on. Only one
lever was presented at each trial in a random and balanced fash-
ion (i.e., left and right levers were presented an equal number of
times) up to 90 trials with a fixed duration of 70 S. The DD proper
sessions consisted in 4 blocks of 10 trials each with an organiza-
tion similar to that described for training days 6–8 differing in
that the nose poke in this case triggers the simultaneous presen-
tation of both levers. One lever is now associated with a small (1
pellet) but immediate reward and the other with a large (4 pel-
lets) but delayed reward (delays: 0, 15, 30, and 45 s respectively in
the 1st, 2nd, 3rd, and 4th blocks). The value attributed to each of
the two levers is balanced between animals. Each block of 10 tri-
als is preceded by two forced-choice trials in which each lever is
individually presented and the pellets are delivered according to
the respective block parameters. The DD sessions were repeated
uninterruptedly for 20 days and the animals that maintained a
robust selection of the favorable lever in the 1st block—5 consec-
utive days with preferences over 70%—were selected for analysis
(N = 8). The area under the curve (AUC) was used as the main
measure of impulsive DD, but data were also analyzed according
to the exponential or the hyperbolic functions (Odum, 2011).
STATISTICAL ANALYSIS
Data is presented as mean± SEM and analyzed using 1- or 2-way
analysis of variance followed by a post-hoc (Tukey) for multiple
comparisons. Independent-samples t-test was used to test for the
drug effect within each delay. Intra-individual comparisons in dif-
ferent paradigms were performed by linear regression analyses.
Results were considered statistically significant if p < 0.05.
RESULTS
PHARMACOLOGICAL VALIDATION
We tested the ability of the VDS to discriminate impulsive behav-
ior in conditions known to decrease or increase impulsivity.
As expected, acute challenge with methamphetamine (VDS1)
diminished, whereas acute treatment with MK-801 (VDS2) aug-
mented, the absolute number of impulsive responses (IR) [VDS1:
F(1, 16) = 5.416 p = 0.033; VDS2: F(1, 18) = 23.258 p < 0.001]
(Figures 2A–D). Additionally, although the number of premature
responses varied in accordancewith the delay in both experiments
[VDS1: F(3, 48) = 90.248 p < 0.001; VDS2: F(3, 54) = 254.888
p < 0.001], this effect was stronger in the saline group as com-
pared to the methamphetamine group [VDS1: F(3, 48) = 5.478
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 154 | 3
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FIGURE 2 | Pharmacological validation of the VDS with
methamphetamine and MK-801. (A–F) Methamphetamine (VDS1) and
MK-801 (VDS2) decreased and increased, respectively, the absolute
number of premature responses (A, C) and the number of premature
responses per available minute of delay (B, D). In the case of
methamphetamine, but not MK-801, this pattern was inverted in the
initial second of the 3 s (i) delay segment (B′, D′). The absolute
(E) and the accumulated (F) average prematurity/trial response profile is
presented in a segmented (500ms periods) fashion for each delay
segment 3 s (i), 6, 12, and 3 s (f). The same analyses are presented to
compare the saline controls in VDS1 and 2 experiments (G–K). No
differences were observed between VDS 1 and 2 nor between the
impulsive behavior in the preceding training sessions (I) indicating that
the VDS permits multiple tests without significant alterations of the
basal behavior. Statistically significant comparisons between delay
segments are marked with a horizontal line over the relevant graph
bars; statistically significant comparisons between groups are marked
over the graph bar of lowest value. ∗P < 0.05; ∗∗P < 0.01; data
presented as mean + S.E.M. 5-csrtt—5 choice serial reaction time task;
DD—delay discounting; VDS—variable delay-to-signal task.
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p = 0.016] and in the MK-801 compared with the respective
saline group [VDS2: F(3, 54) = 26.066 p < 0.001] (Figures 2A,C).
Importantly, the ability of the protocol to detect changes in
impulsivity was further confirmed by an analysis of response rates
(responses per minute of delay–IR/m), which were decreased by
methamphetamine treatment and increased by acute MK-801
injections [VDS1: F(1, 16) = 4.815 p = 0.043; VDS2: F(1, 18) =
17.449 p = 0.001]. Interestingly, this analysis also revealed that
although animals from all groups kept their premature response
rate approximately constant across the 3 delay blocks, they
increased it in the last 3 s delay [VDS1: F(3, 48) = 6.931 p = 0.011;
VDS2: F(3, 54) = 28.166 p < 0.001], an effect that was present in
the saline group but not in the methamphetamine group [VDS1:
F(3, 48) = 8.767 p = 0.005] and was stronger in theMK-801 com-
pared with the respective saline group [VDS2: F(3, 54) = 12.973
p < 0.001] (Figures 2B,D).
To further explore the possibilities offered by VDS in the
characterization of impulsivity, we decided to partition data
from each delay block into 500ms intervals, the results of
which (pooling data from VDS1 and VDS2 together) are
depicted in Figures 2E,F. Overall, this analysis was in line
with our previous data in that methamphetamine treated ani-
mals showed decreased, whereas animals treated with MK-801
had increased, premature responses and response rates com-
pared with saline treated animals, particularly near the end
of each delay block and more obvious across the entire final
delay block [3 s(f)]. This way of looking at our data also
revealed an alteration to the overall response pattern, specifi-
cally of methamphetamine treated animals, in the initial 1000ms
of delay, which prompted us to analyze premature response
rates on this initial period across delays and treatment groups
(Figures 2B′,D′). In this initial period of each delay block,
MK-801 maintained its pro-impulsivity effect [F(1, 18) = 13.780
P = 0.002] whereas methamphetamine failed to reduce impul-
sivity [F(1, 16) = 0 P = ns], with pairwise comparisons even
revealing a significant increase in response rates of metham-
phetamine treated animals in the first (3 s) delay block (t16 =
−3.180 p = 0.006). However, in line with results from the entire
delay period, data from the first 1000ms also showed that
methamphetamine treatment, but not MK-801, prevents the
increase in premature response rates observed in the last delay
block [3 s(f)] of the other experimental groups [VDS1: delay
F(3, 16) = 5.163 P = 0.012 drug′delay F(3, 48) = 7.533 P = 0.002;
VDS2: delay F(3, 18) = 11.918 P < 0.001 drug∗delay F(3, 54) =
3.209 P = 0.063] (Figures 2B′,D′).
To test the presence of a putative effect of VDS repeti-
tion on impulsive behavior (Figures 2G–K), we compared the
performance of the saline groups in VDS1 and VDS2. Apart
from confirming a significant effect of the delay block both
in the number of responses, that varied according to the
amount of delay, [F(3, 48) = 193.262 P < 0.001] and in the
response rate, which was constant in the first 3 delay blocks
but increased dramatically in the last (3 s) period [F(3, 48) =
12.460 P = 0.001], we could not find any significant effect of
experiment on either parameter [number of responses VDS1 vs.
VDS2: F(1, 16) = 2.607 P = ns; response rate VDS1 vs. VDS2:
F(1, 16) = 2.468 P = ns] nor any interaction between experi-
ment and the effects of delay block described above [number
of responses experiment*delay: F(3, 48) = 2.660 P = ns; response
rate experiment∗delay: F(3, 48) = 3.422 P = ns] (Figures 2G,H).
Similarly, the response pattern along the delay blocks was simi-
lar in both saline groups (Figures 2J,K). Importantly, metham-
phetamine and MK-801 at the selected doses had no sedative
or motivational effects, as no differences were observed in the
latency to feed (Figure 3A). On the contrary, the two drugs had
contrasting effects in response latency. While methamphetamine
treatment had no effect in this parameter [F(1, 16) = 0.002 P =
ns] and failed to abrogate a decrease in response latency in
the last delay block [3 s(f)] [delay: F(3, 48) = 14.508 P < 0.001;
drug∗delay: F(3, 48) = 2.494 P = ns], MK-801 had a profound
effect, not only shortening response latencies [F(1, 18) = 7.011
P = 0.016] but also reducing the influence of delay block on them
[delay: F(3, 54) = 24.352 P < 0.001; drug∗delay: F(3, 54) = 10.403
P < 0.001]. (Figures 3B,C).
COMPARISONS WITH REFERENCE PARADIGMS
In order to further characterize the profile of impulsivity assessed
by the VDS, we compared it against reference paradigms, namely
the 5-csrtt (in experiment 1) and DD (in experiment 2). The
parameters used to correlate assessments of impulsivity of the
same animal made in different paradigms were: i) the average
number of impulsive responses in the last 5 days of training before
VDS, a period where impulsive responses were stable (Figure 2I),
ii) the average rate of impulsive responses per minute of delay,
partitioned in segments of 3 S, during the VDS, iii) the aver-
age number of impulsive responses in the different stages of the
FIGURE 3 | Methamphetamine and MK-801 influence on (A) latency to
feed and (B,C) response latency measures. Statistically significant
comparisons between delay segments are marked with a horizontal line over
the relevant graph bars; statistically significant comparisons between groups
are marked over the graph bar of lowest value. ∗P < 0.05; ∗∗P < 0.01; data
presented as mean + S.E.M. VDS—variable delay-to-signal task.
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5-csrtt - 60, 30, 10, 2, and 0.5 s of signal duration—and iv) the
AUC in the DD.While comparisons 5-csrtt and training included
all animals of experiment 1, only animals injected with saline were
used for comparisons with VDS 1 and 2 (Figure 4). The number
of impulsive responses in the training protocol of both VDS 1 and
2 was strongly correlated with the first stage of the 5-csrtt, but
not with later stages of increasing attentional demand (Figure 4;
Table 1). On the contrary, the best correlate of the rate of impul-
sive responses in the VDS was performance in the 10 s stage of
the 5-csrtt, but not in periods with shorter or longer stimulus
presentations (Figure 4; Table 1). Finally, the rate of premature
responses per min in the last delay block of the VDS (as well
as in part of the 12 s delay) was negatively correlated with the
AUC of the DD (of note, in this test a smaller area corresponds
to a higher impulsivity) (Figure 4; Table 1). Importantly, this sig-
nificant correlation also holds true when using the coefficients
derived by fitting an exponential or hyperbolic function to the
response curve.
DISCUSSION
The VDS paradigm was designed according to some simple prin-
ciples: (i) The task (and its training protocol) is performed in a
standard 5-csrtt apparatus in which only the center nose poke
aperture is available. Such approach has been tried before by
Dalley and colleagues (2002) and is intended to increase the
efficiency of the task by reducing the attentional load. (ii) The
training protocol consists in twice daily sessions on a “differential-
reinforcement-of-low-rate” (DRL)-like schedule that quickly (4
days) achieve stability and a high degree of learning. Of notice,
premature responses under DRL are often considered a measure
of impulsivity, particularly under stable schemes such as ours
(Pizzo et al., 2009) and can even be conceptualized as a delay
discounting (Monterosso and Ainslie, 1999) which, although not
the focus of the present paper, can also contribute to enrich the
assessment of impulsivity obtained with the VDS. (iii) The initial
block of 25 trials with 3 s delays until light presentation estab-
lishes a baseline against which results of the other blocks can
be compared and assesses the acquisition of the training pro-
tocol. In our pharmacological assays, baseline behavior did not
differ between saline and methamphetamine (VDS1) or MK-801
FIGURE 4 | Relevant correlations between 5-csrtt and DD performances
and the VDS. (A) The average number of premature responses in the 60 s
stage of the 5-csrtt correlated with the number of premature responses of
both VDS 1 and VDS 2 training periods. (B) Preference for delayed choices
(as measured by the AUC) in DD was inversely correlated with premature
responses in the 3 s (f) period of the VDS. See Table 1 for complete
analyses. 5-csrtt—5 choice serial reaction time task; AUC—area under the
curve; DD—delay discounting; VDS—variable delay-to-signal task.
(VSD2) groups. (iv) The following block of 70 trials exposes
animals to larger delays of 6 and 12 s, randomly presented.
Importantly, this probably induces two sources of behavioral
control, similarly to what happens in mixed-fixed interval (FI)
experiments (Whitaker et al., 2003), that might contribute to the
increased responding observed in the final 3 s-delay block (Baron
and Leinenweber, 1995). (v) The last block consists of 25 trials
with a delay of 3 s before light presentation, in which control
animals present an increased response rate; this is in accordance
with current concepts in behavioral timing, in which the rate of
responding has an inverse relationship with the duration of the
interval (Kirkpatrick, 2002; Guilhardi et al., 2005).
An approach similar to ours, a go/no-go task using delays
of variable duration (9 to 24 s) has been already described by
Mitchell and co-workers (Gubner et al., 2010; Moschak and
Mitchell, 2012). However, while the variable delays constitute the
core of their task, from which measures of impulsive behavior
are taken, the variable intervals in the VDS act as a trigger of
increased impulsivity between the basal 3 s block and the final
3 s block, contributing to unmask manifestations of impulsive
behavior. In addition, while the VDS can be conducted in a sin-
gle session after a training protocol of fixed duration (10 sessions,
5 days), the total number of training sessions in the previously
described task can amount to 11 days, depending on each animal’s
performance.
In a first attempt to characterize VDS, we assessed animals
acutely treated with MK-801 or methamphetamine, two drugs
with well described and opposite effects on impulsive behavior.
Supporting its validity as a test of impulsivity, acute MK-801
treatment (VDS2), which induces enhanced impulsivity (Fletcher
et al., 2011), caused a generalized increase in the number and
rate of premature responses across all delay blocks, whereas acute
challenge with methamphetamine (VDS1), which acts as a sta-
bilizer of impulsive decisions in animals (Richards et al., 1999;
Winstanley et al., 2003) and humans (De Wit et al., 2002), pre-
vented the increase in premature response rates displayed by
control animals in the last (3 s) block. Interestingly, the latter
results seem to be critically dependent on the existence of a pre-
vious block of randomly presented 6/12 s delays in our protocol,
since it was shown that only variable delays, as opposed to fixed
delays, trigger the inhibitory action of acute methamphetamine
upon premature responses on a FI protocol (Hayton et al., 2012).
Besides this effect on the last block, metamphetamine treatment
also resulted in a completely stable response profile across blocks,
independently of the delay. Of notice, this enhanced delay toler-
ance is in accordance with data from DD tasks in which acute
amphetamine induces a delay insensitive behavior (Winstanley
et al., 2003).
To further characterize VDS, we correlated performance in
our test with results of the same animals in one of two standard
paradigms of impulsivity (Winstanley et al., 2010; Dalley et al.,
2011; Dalley and Roiser, 2012): the 5-csrtt (VDS1) and the DD
(VDS2). For these comparisons, VDS delays were divided in bins
of 3 s for several reasons: (i) all delays were multiple of 3 and
therefore this was a convenient option for analyses; (ii) the train-
ing protocol was set at a periodicity of 3 S/trial and therefore this
could be considered the basal value of delay tolerance; (iii) we
Frontiers in Behavioral Neuroscience www.frontiersin.org October 2013 | Volume 7 | Article 154 | 6
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observed that the impulsivity response profile along the delay was
not stable and varied in periods of∼3 s (see Figure 2E).
The strong positive correlation between impulsive behavior in
the initial stage of the 5-csrtt and the training period preceding
the VDS fits with the fact that both tests use a DRL-like sched-
ule, in which premature responses lead to a time-out period. In
contrast, there were almost no significant correlations between
impulsivity behavior in the 5-csrtt and the VDS, which likely
relates to the fact that, in contrast to the training period, pre-
mature responses in the VDS are not “punished.” Indeed, this
protocol difference implies that parameters used as measures
of impulsivity in both tests are of a fundamentally different
nature (percentage of prematurely interrupted trials in the 5-
csrtt vs. number/rate of premature responses in the VDS) and
probably correspond to different types of impulsivity. This idea
is supported by the fact that methamphetamine administration
decreased impulsivity in the VDS (present study) and deci-
sion impulsivity paradigms, including the DD (Richards et al.,
1999; Winstanley et al., 2003), but increased response impul-
sivity in the 5-csrtt (Cole and Robbins, 1987; Fletcher et al.,
2011). In line with this, and despite its overall inhibitory action,
is the observation that metamphetamine increased the rate of
premature responses in the first second of the delay period
might reflect increased response impulsivity. More importantly,
the rate of premature responses in the final 3 s block of the
VDS was strongly and significantly correlated with preference
for delayed choices in the DD, either quantified by the AUC
or by an equivalent parameter in terms of hyperbolic or expo-
nential discounting functions (Odum, 2011). As the latter is the
gold-standard in decision impulsivity assessment, this, together
with data on metamphetamine and MK-801 discussed above,
strongly supports the validity of VDS as a test of impulsive
behavior.
The VDS presents a number of advantageous characteristics
over the available impulsivity paradigms: (i) It has a significantly
shorter training period (10 twice daily sessions) when compared
with the≈35–55 days of 5-csrtt and DD (Winstanley, 2011), (ii) it
requires only one test session, (iii) it is resistant to multiple testing
(has almost no test-retest effect) making it particularly suitable for
longitudinal assays. Our validation assays, namely in the compar-
isons with the 5-csrtt and DD, relied in the intrinsic behavioral
variability of an outbred population (Wistar Han), and not in
artificially induced variability (e.g., by drug treatments or genetic
manipulations), reinforcing the sensitivity of our paradigm in
terms of impulsivity assessment. It should, however, be stated that
the VDS does not replace paradigms like the 5-csrtt, where impul-
sivity is measured in conditions of high attention demand or like
the DD, where an actual choice is presented. Recently, we have
used an earlier version of the VDS to successfully demonstrate
alterations in impulsive behavior in animals with neuropathic
pain (Leite-Almeida et al., 2012).
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Introduction: Ketamine is a general anesthetic (GA) that activates several
neurotransmitter pathways in various part of the brain. The acute effects as GA are the
most well-known and sought-after: to induce loss of responsiveness and to produce
immobility during invasive procedures. However, there is a concern that repeated
exposure might induce behavioral changes that could outlast their acute effect. Most
research in this field describes how GA affects cognition and memory. Our work is to
access if general anesthesia with ketamine can disrupt the motivational behavior trait,
more specifically measuring impulsive behavior.
Methods: Aiming to evaluate the effects of exposure to repeat anesthetic procedures
with ketamine in motivational behavior, we tested animals in a paradigm of impulsive
behavior, the variable delay-to-signal (VDS). In addition, accumbal and striatal medium
spiny neurons morphology was assessed.
Results: Our results demonstrated that previous exposure to ketamine deep-anesthesia
affects inhibitory control (impulsive behavior). Specifically, ketamine exposed animals
maintain a subnormal impulsive rate in the initial periods of the delays. However, in
longer delays while control animals progressively refrain their premature unrewarded
actions, ketamine-exposed animals show a different profile of response with higher
premature unrewarded actions in the last seconds. Animals exposed to multiple
ketamine anesthesia also failed to show an increase in premature unrewarded actions
between the initial and final periods of 3 s delays. These behavioral alterations are
paralleled by an increase in dendritic length of medium spiny neurons of the nucleus
accumbens (NAc).
Conclusions: This demonstrates that ketamine anesthesia acutely affects impulsive
behavior. Interestingly, it also opens up the prospect of using ketamine as an agent
with the ability to modulate impulsivity trait.
Keywords: ketamine, ketamine anesthesia, rat model, impulsive behavior, nucleus accumbens, striatum
INTRODUCTION
General anesthetics (GA) are widely used in invasive surgeries and diagnostic procedures.
Their application is considered to be safe, despite evidences suggesting post-surgery behavioral
impairments. Following the pioneer work by Bedford (1955), several studies have investigated
the relationship between surgical anesthetics and several clinical disturbances involving
deteriorated memory and executive function (for review see Steinmetz et al., 2009). These
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functional alterations are now collectively called postoperative
cognitive dysfunction (POCD). POCD is normally a transient
phenomenon in the majority of patients, although it might gain a
persistent character in aged individuals (Abildstrom et al., 2000;
Selnes et al., 2008). POCD is not entirely understood and seems
to be linked to a multitude of factors, such as the duration of
surgery (Canet et al., 2003), specific procedures such as cardiac
(Goto and Maekawa, 2014) and orthopedic surgery (Shi et al.,
2014), immune response to surgery (Riedel et al., 2014) and to
individual characteristics of each subject such as age or previous
cognitive impairments (Moller et al., 1998; for review see also
Krenk et al., 2010).
Ketamine is an intravenous GA, classified as a dissociative
agent that acts as an antagonist in N-methyl-D-aspartate
(NMDA) glutamate receptor (Maeng et al., 2008). There is
evidence that ketamine interferes with dopamine release as well
(Hancock and Stamford, 1999; Masuzawa et al., 2003) explaining
its effect on executive function and motivation behavior. Others
have argued that its effects mainly stem from its psychotomimetic
properties and its ability to induce psychosis-like behavior in
several animal models (Frohlich and Van Horn, 2014). Despite
the potential behavioral secondary effects, ketamine remains a
very versatile drug used in pain treatment, in general anesthesia
and, more recently, in antidepressant therapy (DeWilde et al.,
2015; Melo et al., 2015). Additionally, it is also used as a
recreational drug with known addictive properties (Sun et al.,
2014).
Despite the growing number of studies on this drug
and associated effects, its impact on impulsive behavior
remains largely unexplored. Impulsivity is a complex construct
encompassing the domains of inhibitory control and decision-
making (Dalley and Roiser, 2012). It is in most cases considered
adaptive (trait impulsivity) but it can assume a disruptive
character in several neuropsychiatric diseases as ADHD,
substance dependence or obsessive-compulsive disorders.
Impulsive behavior is often classified in impulsive action—
compromised ability to inhibit a pre-potent behavior—and
impulsive choices—preference for immediate though suboptimal
over delayed but more compensating options (Evenden and
Ryan, 1996).
Our objective is to study if repeated exposure to ketamine
in the context of general anesthesia might induce changes
in impulsivity using a paradigm that allows evaluating both
impulsive action and delay intolerance.
MATERIALS AND METHODS
Animals
Male Wistar rats (Charles-River Laboratories, Barcelona),
weighing 300–400 g and aged 6 months, were housed (two per
cage) under standard laboratory conditions (12 h light: 12 h
dark cycle, at 22 C, relative humidity of 55%; free access to
food and water). Sixteen animals were randomly assigned to
two experimental groups—a control group (CONT) without
anesthetic exposure and a group with ketamine exposure (KET).
The dietary regimen was restricted to 1 h of food availability
(19:00–20:00), 3 days preceding the initiation of the behavioral
experiments. Body weight was controlled to ensure that it did not
decrease below 85% of the initial value.
A different set of animals was assigned to perform behavioral
evaluation after anesthetic exposure with the same protocol
applied to the variable delay-to-signal (VDS) group. Animals
performed the following behavioral tests: Elevated Plus Maze,
Open Field, Forced Swim Test and Novel Object Recognition
test.
Experiments involving the use of animals followed the
guidelines of European Community Council Directive
2010/63/EU and were approved by the university ethical
committee.
Drugs
For the experimental design the following drug was used:
Ketamine (50mg/ml, Ketalarr, Pfizer, NewYork City, NY, USA)
and as vehicle, saline (NaCl 0.9%).
Anesthetic Procedure
The anesthetic procedure was performed through intra-
peritoneal injections of ketamine according to the following
scheme: an initial anesthetic dose of 100 mg/Kg of ketamine
to induce anesthesia and then two subsequent injections of
50 mg/Kg. Anesthetized animals were placed over a warming
pad with feedback control at 37 C in order to maintain
body temperature. Anesthesia was considered adequate when
animals lost the righting reflex and were irresponsive to tail
pinch. The following dosage (50 mg/ml) was given when
animals regain response to pressure stimuli in the tail. The
anesthesia protocol was applied between the end of the training
sessions and before the VDS test session (see below) in three
GA procedures. Average time of anesthesia was 2.5 h. A
washout period of at least 12 h was applied between the last
anesthetic procedure and the initiation of the VDS protocol (see
Figure 1).
Variable Delay to Signal (VDS)
The VDS task (Leite-Almeida et al., 2013) was performed in
a 25 cm ⇥ 25 cm ⇥ 40 cm (W ⇥ L ⇥ H) operant chamber
(OC; TSE Systems, Bad Homburg, Germany). The selection
wall was slightly curved and presented five squared apertures
(2.5 cm2), equally distributed and elevated 2 cm from the grid
floor (during the VDS procedures only the middle aperture is
available; see below). Similarly, on the opposite wall, an aperture
(food access) led to a pellet dispenser. Each aperture contained
a 3W lamp bulb and an infrared beam system to detect the
activity of the animal. Four OCs were used simultaneously, each
placed in soundproof boxes with individual electrical fans for
ventilation and white noise production. Animals were habituated
to the testing conditions once a day for 4 days (pm session).
In the first 2 sessions, animals were placed in the OC for
15 min with all lights off, access to apertures 1–5 blocked by
metallic caps and 10–15 sugared pellets (45 mg, Bioserv Inc.,
New Jersey, EUA) available in the reward-deliver aperture. In
sessions 3–4, animals were placed in the OCs for 30 min, all
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FIGURE 1 | General organization of the experiment and operational diagrams of the VDS and preceding training protocol. The VDS consisted in two
parts: the training protocol (10 sessions) and the VDS proper (1 session); while in the first the delay-to-signal was fixed (3 s) and pre-signal nose pokes were
punished (TO), in the VDS proper, 2 blocks of 25 trials at 3 s delay were interposed by a block of 70 trials at 6 s and 12 s, pre-signal responses were registered but
not punished with a TO. In both training and VDS the signal duration was set to a maximum of 60 s; the absence of a response within this period was registered as
an omission. TO, timeout; VDS, variable delay-to-signal task.
lights were on and animals had free 2–3 pellets available in
the central (#3) nose poke aperture 10–15 in the reward-deliver
aperture. The protocol for VDS was initiated the following day
and included two phases: (i) training sessions; and (ii) VDS test
(see Figure 1).
(i) Training. Sessions were initiated by turning the house
light on and delivering one sugared pellet in the reward-deliver
aperture, the collection of which started an inter trial interval
(ITI) of 3 s to allow the animal to ingest it. Trials then started,
consisting of a 3 s period with only the house light on (delay
period), followed by lightning of the response aperture #3 for
60 s (response period). Nose pokes in the delay period were
punished with a timeout (TO) period in complete darkness
(5 S) and in the response period (aperture #3 light on) were
rewarded with the delivery of one pellet. These responses were
respectively labeled as premature (PR) or correct responses.
Collection of a food reward always triggered a 3 s ITI, before a
new trial begun. Except for the TO periods, the house light was
always on. Each session consisted of 100 trials or a maximum
time of 30 min (whichever was reached first). Training sessions
occurred twice per day, with a 5 h interval in between, for
five consecutive days. The average number of PR of the overall
group stabilized at⇠30% in the last four sessions of training (see
Figure 2).
(ii) Test. The VDS testing session occurred on a single day
and consisted of 120 trials, similar to those previously described,
with the exception of the delay, which was 3 s in the first
and the last 25 trials, and, either 6 or 12 s in the middle
of the 70 trials randomly attributed by the software leading
to a 3 s (i)—6/12 s—3 s (f) configuration. Importantly, nose
pokes were allowed during the delay period; these premature
responses (PR) were registered and did not trigger TO or reward
deliver.
VDS parameters analyzed are: PR/minute—number of PR
per amount of delay; cumulative prematurity—is the average
of PR accumulated along consecutive bins of 500 ms; latency
to feed—average latency to collect the reward: response
latency—amount of time between the light signal at #3 and
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FIGURE 2 | Training session. Animal performance in both groups does not
differ significantly. Group assignment is performed after the end of the learning
period, with animal randomly assigned to the groups and matched for
performance in premature responses (PR).
response. Latencies are presented as averaged times, i.e., sum
of response times divided by the number of trials at each
block—3 s (i), 6 s, 12 s or 12 s.
Elevated Plus Maze
To assess anxiety-like behavior, animals were tested on the
elevated-plus maze (MED-NIRPMNR; Med Associates, St
Albans, VT, USA) as previously described (Pêgo et al., 2008).
Animals were placed at the central hub facing the open-closed
arm intersection and were allowed to explore the maze for
5 min. An arm entry was considered if the four paws were
positioned within the arm. The test was filmed and the
ratio between time in open arms and time in closed arms
was subsequently quantified. Activity in the open arms was
calculated as open arm entries percentage (entries into the open
arms/total entries into all arms) and time spent in open arm
percentage (time spent in the open arms/total time spent in
all arms). The degree of anxiety was indirectly related to the
time spent in the open arms and the number of open arm
entries.
Open Field
To assess locomotor activity, rats were placed in an open-field
apparatus (43.2 (length) cm ⇥ 43.2 (width) cm ⇥ 30.5
(height) cm, transparent acrylic walls and white floor, Med
Associates) in a room illuminated by white light. Instant position
was monitored over a period of 5 min by an array of two 16 beam
infrared arrays. Total distance and average speed were used as a
measure of locomotor activity.
Forced Swim Test
Learned helplessness was evaluated in the forced-swim test on the
last day of exposure to uCMS. Twenty-four hours after a pre-test
session (10 min), rats were placed in cylinders filled with water
(25 C; depth 30 cm) for a period of 5 min. Test sessions were
assessed using a camera connected to a video tracking system
(Viewpoint, Lyon, France); the system automatically calculated
immobility time and latency to immobility. Learned helplessness
behavior was defined as an increase in time of immobility and a
decrease in latency to immobility.
Novel Object Recognition
Recognition memory of the animals was assessed using an
adapted version of the non-matching-to-sample learning task as
previously described (Bevins and Besheer, 2006).
Histological Procedures
After behavioral evaluation, five rats from each group were
perfused transcardially with saline (NaCl 0.9%) under deep
pentobarbital anesthesia. Brains were removed and kept in
Golgi-Cox solution for 15 days and then transferred to a
30% sucrose solution for 5 days (Glaser and Van der Loos,
1981). Coronal sections (200 µm) were obtained using a
vibratome and collected in 6% sucrose and blotted dry onto
gelatin-coated microscope slides. They were alkalinized in
18.7% ammonia, developed in Dektol (Kodak, Rochester,
NY, USA), fixed in Kodak Rapid Fix, dehydrated and xylene-
cleared before coverslipping. Dendritic arborization was then
analyzed in the nucleus accumbens (NAc) and Striatum
(Str). Selected neurons had every branch of the dendritic
tree reconstructed using a motorized microscope (Olympus
BX51; Olympus, Tokyo, Japan) and Neurolucida v10 software
(Microbrightfield, Williston, VT, USA) and three-dimensional
analysis of the reconstructed neurons was performed using
Neurolucida Explorer v10 software (Microbrightfield). For each
animal, 20 neurons were reconstructed and measurements
from individual neurons from each animal were averaged.
The following dendritic morphology parameters were
examined: dendritic length and the number of primary
dendrites and dendritic branching points were compared
across experimental groups. The observer who made the
neuronal reconstruction was blind on the constitution of the
groups.
Statistical analysis
Data is presented as mean ± SEM and analyzed using two-way
analysis of variance followed by a post hoc (Bonferroni)
for multiple comparisons for analysis of the VDS results.
Independent-samples t-test was used to test for the drug effect
within each delay; behavioral results in the elevated plus maze,
open field, forced swimming and novel object recognition test;
and for analysis of neuronal dendritic length. The spearman rank
correlation test was used to test correlation between different
variables. Results were considered statistically significant if
p< 0.05.
RESULTS
Impulsivity
We tested the effect of repeated anesthetic exposure to ketamine
in impulsivity behavior. General anesthesia with ketamine had
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FIGURE 3 | VDS test results general anesthesia with ketamine had no effect in the absolute number of PR; however, the number of PR varied
according to the delay (A). Normalized PR per minute of available delay (PR/m) varied according to the delay 3 s (i), 6 s, 12 s and 3 s (f). Decrease of
PR/m in animals treated with ketamine compared to the control animals in both 3 s (i) and 3 s (f) delay periods (B). Decrease of PR for the KET animals
when compared with CONT animals in the 0–1000 ms period (C). Absolute (D–G) and the accumulated (H–K) average prematurity/premature responses
profile is presented in a segmented (500 ms periods) fashion for each delay segment 3 s (i), 6 s, 12 s and 3 s (f). No differences were observed in the
latency to feed and no overall effect was detected across different delays (L). No effects were observed in response latencies between experimental groups
(M). (⇤p < 0.05; ⇤⇤p < 0.01; ##p < 0.01; ###p < 0.001; ⇤significances refer to differences between groups, #significances refer to differences between
different delays).
no effect in the absolute number of PR (F(1,112) = 0.6795 P = ns);
however, the number of PR varied according to the delay
(F(3,112) = 59.74, P < 0.0001; Figure 3A). We also observed
that the normalized PR per minute of available delay (PR/m)
varied according to the delay 3 s (i), 6 s, 12 s and 3 s (f)
(F(3,112) = 4.087, P = 0.0085) and that it was significantly
decreased for animals treated with ketamine compared to the
control animals (F(1,112) = 10.66, P = 0.0015) in both 3 s (i)
and 3 s (f) delay periods (Figure 3B). Our results revealed that
animals from both groups, CONT and KET, kept their PR/m
rate relatively constant across the initial blocks, while for the last
3 s delay, we observed a difference in the IR: CONT animals
showed a normal increase in PR/m, while KET were insensitive
to the exposure to large delays (F(1,112) = 6.931, P = 0.0015;
Figure 3B).
To further explore the possibilities offered by VDS in
the characterization of impulsivity and according to our
previous studies (Leite-Almeida et al., 2013), we partitioned
each delay block into 500 ms intervals (Figures 3D–K). This
analysis confirmed our previous data showing a decrease
of PR for the KET animals when compared with CONT
animals (delay: F(3,112) = 10.44, P < 0.0001; exposure to
ketamine: F(1,112) = 14.73, P = 0.0002; Figure 3C). In the
3 s (i) and 6 s delays, we observed no differences between
groups. But in the 12 s delay, KET exposure decreased
PR rate in the first part (up to 6000 ms) but not in
the second part (6000–12,000 ms) of the delay, suggesting
a heightened impulsive behavior (p(t = 0.880, dF = 28) = 0.0075;
Figure 3C). On the contrary, in the last delay period [3 s (f)]
(p(t = 2.654, dF = 28) = 0.0130), ketamine prevented an increase in
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PR that in normal conditions is observed after exposure to long
delays (Figure 3C). These observations are not due to sedative
or motivational effect at the selected doses as no differences
were observed in the latency to feed and no overall effect was
detected across different delays (F(3,112) = 2.504, P = 0.0629;
Figure 3L). No effects were observed in response latencies
FIGURE 4 | Behavior evaluation performed to validate the model of anesthesia exposure: animals exposed to ketamine anesthesia performed similarly to
control animals in the Elevated Plus Maze (A), Novel Object Recognition Test (B), Open Field (C,D), Forced Swimming Test (E,F).
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between experimental groups (drug⇤delay: F(3,112) = 1.886,
P = ns; Figure 3M).
Other Behavioral Evaluations
In order to rule out the effect of ketamine anesthesia
behavioral dimensions that could interact with VDS results,
we performed evaluations in a different group of animals
not assigned to perform the VDS paradigm. Results show
that animals exposed to ketamine anesthesia have similar
performance to control group concerning Elevated Plus Maze
(Figure 4A), Novel Object Recognition Test (Figure 4B),
Forced Swimming test (Figures 4C,D) and Open field
(Figures 4E,F).
Neuronal Morphology
We performed neuronal dendritic reconstruction. The analysis
of dendritic branching in the NAc showed a significant increase
in dendritic length in animals exposed to ketamine anesthesia
p(t = 3.880, dF = 28) = 0.0047 (Figure 5A) and no difference in
the striatum analysis (Figure 5B). No differences were found
concerning dendritic spine analysis.
Correlation of VDS Performance With
Neuronal Morphology
We found a significant negative correlation between NAc
neuronal dendritic length and the number of absolute PR
in the initial 3 s delay (R =  0.67, P = 0.039) and final
3 s delay PR 3 s (i) (R =  0.66, P = 0.041). Concerning
the ratio of PR/minute we also found a negative correlation
between the values in the initial 3 s period and dendritic
length of NAc neurons (R =  0.740, p = 0.001) (Figures 6A,B;
Table 1).
DISCUSSION
In this work, we investigated the existence of possible alterations
in executive function induced by consecutive ketamine anesthetic
administration using impulsivity as surrogate readout as assessed
by the VDS. We observed that KET-multiple exposure abolished
the increase in the rate of PR (PR/minute) that is generally
observed in the last block [3 s (f)] after the long-delay
trials (6 and 12 s; Leite-Almeida et al., 2013). This effect
was preserved in control animals. Curiously, over the course
of long 6 s and 12 s delays, KET animals increased their
PR above normal levels. It is important to notice that we
found no differences in the latencies to feed or changes in
animal weight, indicating that both KET-exposed animals and
controls were equally motivated during the performance of
the test. Additionally, we have analyzed the neuronal dendritic
architecture in the NAc and striatum; our analysis revealed an
increased average dendritic length in the first. Also, we observed
increased impulsivity at the 3 s (i) and 3 s (f) blocks were
associated with longer dendritic length in the NAcmedium spiny
neurons.
The VDS, which was developed in our lab, was designed
and validated to evaluate impulsive behavior in a rat model
(Leite-Almeida et al., 2013). In this paradigm, delay intolerance
manifests as a robust increase of PR in the 3 s (f) segment when
compared to the 3 s (i), i.e., after exposure to large 6 s and 12 s
delays. This increment in the rate of impulsive responses as well
as the rate of impulsive responses in the later periods of the 12 s
segment has been shown to correlate with discounting steepness
in the delay discounting (DD) paradigm (Evenden and Ryan,
1996). Additionally, impulsive responses in the training phase
reflect action impulsivity; the construct at this stage is similar
to that of the 5-choice serial reaction time task (5-CSRTT; Carli
et al., 1983).
The KET group displayed a smaller PR/min in the 3 s (i)
delay, even when the analysis was confined to the first 1000 ms, a
parameter that is closely associated with impulsive action (Leite-
Almeida et al., 2013). In previous works, using Sprague Dawley
(Nemeth et al., 2010) and Lister Hooded (Smith et al., 2011)
rats under the influence of acute sub-anesthetic doses of KET
showed no difference in impulsive responses in the 5-CSRTT.
Similarly, Nikiforuk and Popik (2014) observed that exposure
to both single or repeated sub-anesthetic doses of ketamine
produced no differences in the baseline performance of any of
the 5-CSRTT performance measures, such as correct/incorrect
responses, omissions, accuracy and perseverant responding).
However, in both experimental conditions an increase in
omissions was detected without alterations in motivational
aspects of the response. On the contrary, Oliver and coworkers
revealed that acute administration of sub-anesthetic doses of
ketamine increased the CD1 mice impulsive behavior, when
performing the 5-CSRTT (Oliver et al., 2009). Indeed, several
studies reported that NMDA antagonists (other than ketamine)
increase impulsivity in the 5-CSRTT. That is the case of acute
treatment with MK-801 or phencyclidine (Paine and Carlezon,
2009; Thomson et al., 2011; Barnes et al., 2012). Similarly, our
group has shown that an acute challenge with MK-801 is able to
increase all measures of impulsive behavior in the VDS (Leite-
Almeida et al., 2013). On the other hand, chronic treatment may
display a different behavioral pattern, either reduced PR during
a 24-h drug withdrawal (Paine and Carlezon, 2009) or had no
effect (Thomson et al., 2011; Barnes et al., 2012). Until now,
most research seems to show a tendency of NMDA antagonists
to increase impulsive behavior after an acute exposure, while
on sub-chronic and chronic regimens the response seems to be
towards a decrease in impulsive response particularly if the test
is made during the withdrawn period. Our study shows a more
complex picture. In line with the above studies, we observed a
decrease in basal impulsive response. However, when analyzing
the patterns of response along the delay period in intervals of
TABLE 1 | Correlation table (Pearson r2 values; P values; ⇤p< 0.05).
Dendritic length nucleus accumbens
R2 p
Premature responses/minute 3 s (i)  0.89⇤ 0.001093474
Premature responses/minute 6 s  0.27 0.448276565
Premature responses/minute 12 s 0.09 0.811282518
Premature responses/minute 3 s (f)  0.57 0.093003748
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FIGURE 5 | Neuronal dendritic reconstruction in the nucleus accumbens (NAc). Increase in dendritic length in animals exposed to ketamine anesthesia
(A) and no difference in the striatum analysis (B). (⇤⇤p < 0.01).
FIGURE 6 | Plot graph; values of ratio of PR/minute in the 3 s initial period (A); values of ratio of PR/minute in the 3 s final period (B); (PR, premature responses).
500 ms, it was evident that KET animals increased their PR/min
towards the end of the delay overcoming the CONT group.
In other words, while CONT animals, after some premature
unrewarded responses, were able to correct their behavior, KET
animals failed to adjust and steadily increase their prematurity
rate, suggesting failures in their inhibitory control. In addition,
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KET animals failed to show a robust increase in the PR/min
between [3 s (i)] and [3 s (f)], which is normally observed
after the exposure to large delays (Leite-Almeida et al., 2013).
The PR/min in the [3 s (f)] is strongly correlated with the DD
behavior, i.e., higher PR/min is associated to a preference for
immediate (but smaller) choices in the DD (Leite-Almeida et al.,
2013). Our findings suggest that ketamine disrupted a response
correlated with performance inDD. These findings are supported
by data from studies that show changes in DD performance
after administration of ketamine and other NMDA antagonists
such as memantine and MK-801 (Floresco et al., 2008; Cottone
et al., 2013; Yates et al., 2015). Specifically, Yates et al. (2015)
observed that ketamine decreased the sensitivity to reinforcer
amount in DD, while Cottone showed that ketamine increased
the choice for small immediate reward (Cottone et al., 2013) and
Floresco reported that ketamine induced a decrease in tolerance
for delayed rewards (Floresco et al., 2008).
No significant differences were observed in response and feed
latencies which is concordant with the work of Nelson et al.
(2002) where repeated ketamine administration was shown to
have no impact on animals’ capacity to perform the sustained
attention task.
Food availability is also a concern and a limitation in operant
behavior protocols. Research animals are food restricted in order
to get themotivation for performing the task. The specific feeding
regimen was applied according to the previously published
protocol of the VDS paradigm (Leite-Almeida et al., 2013) and
following the recommendations for daily food intake previously
reported in other operant protocols (Bari et al., 2008). However,
binge access to food might also promote the development of a
higher impulsive trait (Vanderschuren and Ahmed, 2013).
VDS results were also not affected by emotional, locomotory
or cognitive altered behavior as there were no differences
between experimental and control group in these behavioral
tests.
Chambers and Potenza (2003) proposed two main circuits
to control impulsive response. A primary circuit consisting of
parallel loops of neuronal projections from the prefrontal cortex,
to the ventral Str (including the NAc), to the thalamus and
then back to the cortex and a second circuit would supply
the primary with autonomic, affective, motor and memory
information necessary for a proper shaping of the output. The
role of NAc in impulsive behavior was first shown by Cardinal
et al. (2001), who described that bilateral lesion of the NAc but
not of the anterior cingulate cortex or medial prefrontal cortex,
resulted in more impulsive choices in delayed reinforcement
choice task. In the DD, NAc lesioned rats were less impulsive, but
only when the delay was changed between sessions, suggesting
that NAc lesions impaired learning or adaptation to changes
in delay reinforcement but did not affect tolerance to delays
(Acheson et al., 2006). On the contrary, da Costa Araújo et al.
(2009) showed that NAc lesioned rodents had changes in inter-
temporal choice behavior preferring immediate over delayed
reinforcement in an adjusting-delay approach. In our work, KET
exposure increased dendritic arborization in the NAc medium
spiny neurons but not in the striatum. Drugs of abuse with
known effect in impulsive behavior, such as amphetamine and
cocaine, are known to induce changes in neuronal architecture in
the NAc (Robinson and Kolb, 2004). Ketamine is a GA that is also
used as a drug of abuse. Despite its relatively short half-life, some
of the effects of ketamine are known to be long-lived, namely
through the activation of signaling pathways following the acute
blockage of NMDA receptors and that are responsible for
the neuronal changes namely synaptic and dendritic modeling.
Exposure to a single dose of ketamine is known to increase the
levels of activity regulated cytoskeletal protein (Arc), glutamate
AMPA receptor-1 (GluR1), postsynaptic density protein-95
(PSD95) and synapsin I, all of them of importance in dendritic
and synaptic remodeling (Li et al., 2010). Ketamine also has
been shown to regulate the levels of neurotrophic factors
such as brain derived neurotrophic factor (BDNF), which has
been related with processes such as neurogenesis and synaptic
protein expression (Kovalchuk et al., 2002). Ketamine also
affects the regulation of signaling pathways such as mammalian
target of rapamicin (mTOR), is a critical mediator of protein
synthesis (Ma and Blenis, 2009) including dendritic/synaptic
proteins (Liu-Yesucevitz et al., 2011). Indeed, the inactivation of
mTOR pathway blocked the antidepressant effect of ketamine
(Li et al., 2010). Interestingly, Sabino et al. (2013) showed
that mTOR activation is needed to achieve a reduction of
alcohol consumption in alcohol-preferring rats, showing that this
pathway is also implicated in the build-up of other behaviors such
as addiction. Our findings of changes in neuronal architecture
after exposure to ketamine supports the known effect in synaptic
protein expression factors and regulation of protein synthesis
signaling pathways such as the aforementioned mTOR pathway.
The synthesis of synaptic proteins important for neuroplasticity
is one of the potentially critical steps for ketamine action (Duman
et al., 2012). Our findings on dendritic organization largely reflect
these observations.
In summary, this study demonstrated that a multiple
exposure to ketamine anesthesia affects impulsive behavior.
We demonstrated that this abnormal inhibitory control is
associated with an increase in neuronal dendritic length of the
NAc. In human patients exposed to anesthetic procedures, the
postoperative cognitive deficits, manifested by their inability
to engage successfully tasks at home or work, have also been
reported, though impulsive behavior has not been specifically
measured. We cannot therefore exclude the possibility
that alterations in impulsive behavior might also influence
postoperative period impairments.
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Ketamine is a versatile drug used in clinical practice for sedation, analgesia or anesthesia. 
The work described in this thesis provides new insights for ketamine use in the modulation of 
several behavioral dimensions, namely mood and impulsive behavior. 
 
Several neurological networks within the brain are of paramount importance in the 
establishment of normal behavior. Neurons are the unitary base that support this network. 
Brain connectivity is a concept based in physical and functional wiring of the neuronal activity 
through the whole brain. Changes in brain connectivity are a hallmark of both pathological 
changes in the central nervous system, and of behavioral traits. Through this thesis, we show 
that ketamine has the ability to induce changes in neuronal network architecture, and cause 
behavioral changes in animal models of depressed like behavior and increased impulsivity. 
These characteristics make ketamine a potential game changer in different settings of 
behavioral modulation. 
 
Our work focuses in the action of Ketamine as both antidepressant and impulsive behavior 
modulator. The fast acting antidepressant effect of ketamine and the acute effect in 
impulsivity are both known. Our main objective was to study the effect of repeated use of 
ketamine, while avoiding the establishment of models of chronic administration. The objective 
was to establish animal models, in which ketamine was studied in an interventional and 
therapeutic manner avoiding the establishment of models of addiction or schizophrenic-like 
behavior. 
 
We used two distinct animal models and approaches to answer questions regarding the effect 
of ketamine in two different behavior domains: depression and impulsivity. 
 
 
Animal model of depression 
	 77 
 
The main aim of our work was to characterize the impact of ketamine on current 
antidepressant therapy strategies. To answer this question, we selected an animal model that 
allowed us to reproduce a depressive-like phenotype in rodents that could be reverted by 
antidepressants. We chose the unpredictable CMS animal model of depressive-like behavior, 
which allowed us to mimic the changes induced in the central nervous system and behavior 
observed in humans with major depression. This animal model has been extensively used 
and reviewed as one of the gold standards in the study of the etiology of major depression 
and in preclinical development of antidepressant drugs (Willner et al, 2005). This model 
replicates not only behavioral changes but also neuronal structural changes that are 
associated with depression in humans, specifically in brain areas such as the hippocampus, 
PFC and NAc. This animal model is also known for being responsive to antidepressant 
treatment with reversal of the behavioral correlates of the clinical core symptoms of 
depression, namely, anhedonia and helplessness. It is a very valuable tool to assess the 
cellular and systemic mechanisms underlying depression and antidepressant drugs 
mechanisms of action.  
 
The first study in rodents exposed to chronic stressors as a model for depressive-like 
behavior was developed by Katz (1982) and the main behavioral endpoint was the evaluation 
of sucrose preference, believed to be akin to the impairments in reward processing, which are 
the foundation for one of the core symptoms of major depression, anhedonia. The concept of 
exposure to stressors evolved with the elimination of noxious stimuli, and in the late 80’s Paul 
Willner’s group developed the chronic mild stress (CMS) paradigm (Willner et al,1987). The 
construct for this model is that depressive disorders, in humans, typically, develop after long 
lasting exposure to uncontrollable and unpredictable mild daily stressors (Kessler et al,1997). 
The validity of the model was confirmed by a reversion of the deficit in hedonic behavior as a 
response to chronic treatment with conventional antidepressants (Willner et al,1987). The 
adoption of the CMS model in rodents as a gold standard to study major depression produced 
extensive knowledge about the behavioral endpoints. The exposure of rodents to CMS 
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produced for example: increased immobility in the forced swim test, reduced self-care, 
changes in sexual behavior, increase in REM sleep latency (Willner et al, 1995). Nowadays, 
with more than two decades of use, the CMS model is known to be of paramount relevance to 
the study of the etiology of major depression. The exposure of rodents to CMS protocol 
produces behavioral, neuro-biological and neuronal structure changes that can be reversed 
with antidepressant treatment (Hill et al, 2012, Bessa et al, 2009; Bessa et al, 2013). 
Additionally, the CMS model is extensively used in the evaluation of antidepressant potential 
of drugs in rodents, as well as, allowing to investigate potential means of shortening the onset 
latency of antidepressant action using co-administration of drugs (Papp et al, 1996). 
For these characteristics, we used the CMS animal model of depressive-like behavior to test 
the effect of ketamine when given in co-administration with other antidepressants. 
 
 
The effect of Ketamine in the reversion of depressive like behavior  
 
Several molecular players take part in the etiology of depressive disorders. The most 
commonly defended theory, the so called “monoaminergic hypothesis”, postulates that 
depression is the result of an imbalance in brain monoamines, and is the basis of the 
development of current antidepressant strategies (Delgado et al, 2000). The first developed 
antidepressants had a less selective action, such as tricyclic antidepressants, but they 
evolved to more selective mechanisms of action, such as SSRIs (Alamo et al, 2009). Despite 
a wide range of antidepressant drugs, the major issues concerning current treatments are the 
lack of efficacy and the delayed onset of clinical efficacy (Rush et al, 2006). In recent years, it 
has become clear that neurotransmitters other than monoamines are involved in major 
depression, namely the glutamatergic system (Sanacora et al, 2012). Glutamate is the most 
common excitatory neurotransmitter in human brain, in particular in cortical areas, and plays 
a major role in processes such as cell plasticity and neuronal development. Ketamine is a 
NMDA competitive antagonist with known antidepressant effects reported both in animal 
models and in clinical studies (Garcia et al, 2008; Berman et al, 2000; Zarate et al, 2006, 
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Phelps et al, 2008). The most striking feature concerning ketamine antidepressant activity is 
the fast acting and long lasting behavioral effect. We hypothesized that these characteristics 
are important to achieve a therapeutic strategy that shortens the time lag between the 
beginning of treatment and the clinical response that can endanger the vulnerable patient 
inside this time frame. 
In order to test our hypothesis, we used antidepressants belonging to two different families 
with established efficacy in CMS: imipramine, a tricyclic antidepressant, and fluoxetine, a 
selective 5-HT reuptake inhibitor. The efficacy of both antidepressants in this model has 
already been documented (Bessa et al, 2009). The efficacy of ketamine in sub-anesthetic 
doses as a fast-acting antidepressant in rodents has also been previously reported (Li et al, 
2011). Additionally, ketamine also as anxiolytic, sedative and psychomimetic effects. In fact, 
one of the applications of ketamine in rodents is the development of an animal model of 
schizophrenia. In order to focus our behavioral evaluation on the antidepressant endpoints, 
we ruled out that the used dosage (10 mg/Kg) could induce psychomimetic changes in 
rodents. 
The behavioral endpoints of the CMS are to develop anhedonia and learned helplessness, 
both characteristic traits of major depression in humans. The use of the sucrose preference 
test allowed us to observe the temporal response to the antidepressant treatment in 
anhedonia. We were able to confirm that the addition of ketamine during the beginning of the 
antidepressant treatment was able to anticipate recovery from anhedonia and that this 
response was sustained in time. In the remaining behavioral evaluation, ketamine increased 
the efficiency in recovery when given with fluoxetine, but not with imipramine. Given that 
fluoxetine usually is associated with a slower onset of recovery, probably the effect of addition 
of ketamine is a stronger one. The addition of ketamine to both antidepressants also 
produced anxiolytic effects. (See Chapter 2) 
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Morphological correlates of the antidepressant effect of ketamine 
 
In the last several years it has become increasingly recognized that maladaptive changes in 
the structure and function of excitatory/inhibitory circuits have a primary role in the 
pathophysiology of mood disorders. The use of neuroimaging technics revealed 
morphological changes in brains of depressed patients. Study of the brain structure in the 
CMS rodent model also revealed that stress induces changes in structure and morphology in 
cortical and limbic areas, such as the hippocampus and NAc and treatment with both 
monoaminergic and non-monoaminergic antidepressants was able to reverse the changes in 
dendritic arborization and spine density induced by CMS (Bessa et al 2009; Bessa et al, 
2013). In the present work, we found similar changes in neuronal morphology, namely in 
dendritic arborization and in spine density, induced by chronic exposure to stressors. The 
effect of treatment was a generalized reversal of the effects induced by chronic stress, with 
special focus on the shift of spine morphology to a more mature phenotype (mushroom 
spines). The acute effect of ketamine in dendritic spines has already been shown and is 
present as soon as 2 hours after administration, with a peak of maturation to mushroom 
spines at 24h (Lie et al, 2010). In our work addition of ketamine to the antidepressants 
resulted in a higher degree of differentiation of spine morphology in some areas (Chapter 2). 
Despite not having performed serial time point analysis we postulate that changes were the 
summation of the effect of the antidepressant with the immediate acute effects of ketamine. 
Time point analysis is a tool that we can further develop in order to evaluate the individual 
effect of each drug and the temporal profile of dendritic spine development. 
 
 
The molecular targets of ketamine are extremely important to establish the effects of this 
drug. Beside the fast antidepressant effect, ketamine has well known described acute effects 
in behavior. It is an established recreational drug with widespread use as abuse substance. 
However, ketamine is also a very useful drug in the practice of contemporary medicine. In our 
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work, we used the behavioral dimension impulsivity to measure the lasting effect of exposure 
to ketamine anesthesia.  
 
 
Animal model of impulsivity 
 
Impulsive response can be measured with a wide range of behavioral paradigms: stop-signal 
task (SST)(Logan et al, 1984), the go/no-go task (de Wit et al, 2002), the 5-CSRT (Robbins et 
al, 2002) the Differential Reinforcement of Lower Rates of Behavior (DRL) task (Seiden et al, 
1979), and the simple reaction time task (SRTT) (Amalric and Koob, 1987). Despite the 
existence of all these behavioral paradigms, the test that is most commonly used and is 
considered the gold standard is the 5-CSRT. The common feature of all these 5 tests is the 
ability to evaluate premature responses (PR). The specific design of the different tasks allows 
further evaluation of certain parameters: the SST and go/no-go tasks can measure the ability 
to inhibit a motor response (Eagle and Baunez, 2010); the 5-CSRT, DRL and SRTT involve 
“waiting” before making a response to obtain a reinforcement. 
The measurement of impulsive choice, which reflects the preference for immediately available 
small rewards over larger but more delayed ones, is commonly evaluated with temporal 
discounting procedures such as the delay discounting task (DDT)(Ainslie et al, 1975), effort 
discounting paradigms (Floresco et al, 2008), probabilistic discounting tasks (St Onge and 
Floresco, 2009) and gambling-like tasks, such as the Iowa Gambling Task (Bechara et al, 
1994). Most of these tasks might be applied both to rodents and humans, obviously with the 
necessary technical adaptations.  
To clarify if chronic ketamine anesthesia affected impulsive behavior, we used a new in-
house developed paradigm of assessment of impulsivity (Leite-Almeida et al, 2013), the 
Variable Delay to Signal Task (VDS; View Chapter 3). This new paradigm provides rapid and 
simultaneous assessment of response and decision impulsivity in rodents. Being aware that 
DA plays an important role in the process of impulsive response modeling, and that DA 
agonist medication is related to the onset of various impulse-control behavior problems such 
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as pathological gambling or compulsive drug-seeking (Gallagher et al, 2007; Dagher and 
Robbins, 2009; Moore et al, 2014), it became particularly relevant to pharmacologically 
validate the VDS protocol which was achieved with the use of two drugs known to modulate 
DA: MK-801 and methamphetamine. 
The VDS presented several advantageous characteristics over the other available impulsivity 
paradigms, such as: a significantly shorter training period when compared with the 5-CSRT 
and DD; only one test session required; and the suitability to retest the animals without losing 
the test effect.  
The characteristics of the VDS test, and the fact that it has earlier been used to successfully 
demonstrate alterations in impulsive behavior in a rodent model of neuropathic pain (Leite-
Almeida et al, 2012), made this test a good tool to access the long-lasting effect of ketamine 
after recovery of an anesthetic procedure. Procedures that take a longer period of time to 
access impulsivity could induce bias in the results when trying to evaluate the acute effect of 
the exposure. The short duration of the learning period (shaping) as well as the assessment 
period be accomplished in one day were the reasons that led us to choose the paradigm. 
Other feature was the feasibility to repeat the test, with the possibility of new experimental 
designs.  
So far, most of the work concerning ketamine effect in impulsive behavior focus either on the 
acute effect of sub anesthetic acute dosages or on the potential of development of addiction 
response with chronic administration of the drug. One particular study by Agnieska focuses 
on the use of ketamine either in a chronic scheme or an acute scheme. In the chronic scheme 
ketamine was administered for 10 days, and the evaluation was performed 22 hours after and 
for 4 consecutive days (Nikiforuk and Popik, 2014). Despite some similarities, there are 
important differences: ketamine in this study has always been administered in sub-anesthetic 
dosages, and the timeline is similar to protocol used to induce schizophrenia-like behavior. 
For these reasons, our work is unique in the aim to assess the short-term/non-acute effects of 
repeated general anesthesia using ketamine, on motivational behavior, because the 
experimental protocol avoids development of both schizophrenia and addiction phenotypes, 
while focusing in the effect in impulsive behavior after ketamine anesthesia. 
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As previously discussed, in VDS, delay intolerance manifests itself as a robust increase of PR 
in the 3 s (f) segment when compared to the 3 s (i), i.e., after exposure to large 6 s and 12 s 
delays. This increment in the rate of impulsive responses as well as the rate of impulsive 
responses in the later periods of the 12 s segment has been shown to correlate with 
discounting steepness in the delay discounting paradigm (Evenden and Ryan, 1996). 
Additionally, impulsive responses in the training phase reflect action impulsivity; the construct 
at this stage is similar to that of the 5-choice serial reaction time task (5-CSRTT; Carli et al, 
1983) (See Chapter 3).  
The exposure of animals to variable delays in order to perform the task was specifically 
designed to boost the impulsivity response during the last period of fixed delay of 3 seconds. 
That is the expected response in controls (See Chapter 3 and Chapter 4). 
In our study there was a decrease in basal impulsive response, in accordance with expected 
response (Leite-Almeida et al, 2013). However, when analyzing the patterns of response 
along the delay period in intervals of 500 ms, it was evident that animals exposed to ketamine 
increased their PR/min towards the end of the delay. In other words, while control animals 
were able to correct their behavior, after some premature unrewarded responses, ketamine 
exposed animals failed to adjust and steadily increase their prematurity rate, suggesting 
failures in their inhibitory control. In addition, the exposed animals failed to show a robust 
increase in the PR/min between [3 s (i)] and [3 s (f)], which is normally observed after the 
exposure to large delays (Leite-Almeida et al, 2013). 
The morphological changes associated to the antidepressant effect of ketamine shows that 
this drug has a potent neurotrophic effect, causing acute changes in neuronal morphology. In 
accordance, we investigated whether similar changes occurred in neuronal dendrites in key 
areas known to be involved in decision-making processes, such as the Str and the NAc. In 
animals exposed to ketamine we found an increase in the length of neuronal dendrites in 
NAc. We previously have witnessed an increase in neuronal dendritic length in NAc in 
animals exposed to CMS (Bessa et al, 2013). Our work (see Chapter 2) shows that when 
depressed rodents are treated with sub-anesthetic doses of ketamine, there is a recovery 
toward the neuronal morphology of control animals.  
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In addition to the neurotrophic effect, ketamine also induces an increase in extracellular DA 
acutely. Most studies show that within minutes of cessation of exposure to ketamine, 
extracellular DA starts to decrease back to normal levels. We did not evaluate the 
concentration of DA in the brain, but we performed western blot analysis to access dopamine 
2 receptor (D2R) isoforms in the same areas. The result of our analysis was a decrease in 
relative ratio in both glycosylated and non-glycosylated isoforms of D2R in the Str. Subjects 
with chronic consumption of metamphetamine have an increased impulsive trait, which 
correlates with a decrease in the availability of D2R in the Str and NAc (Lee et al, 2009).  
The molecular actions of ketamine are known to set effect in a short period of time, and to be 
dependent on rapid protein synthesis, namely of BDNF, PSD-95, GLuR1 and synapsin and 
activation of intracellular pathways such as mTOR, all of them physiologically relevant for 
synaptic plasticity mechanisms, neuronal growth, differentiation and synaptogenesis (Hoeffer 
et al, 2010; Kavalali et al, 2015).  
This is the main mechanism that is thought to underlie the fast antidepressant effect of 
ketamine. When we evaluated the effect of ketamine as an adjuvant to antidepressants, we 
found morphological changes as well as molecular adaptations in the NAc. The NAc is a 
determining region in the formation of motivational behavior as well in anhedonia which 
suggests that, putatively, ketamine induced improvement in anhedonia involves these 
alterations.  
Ketamine has different effects that are dose-dependent. For instance, the activity of ketamine 
as an antidepressant is only described for sub-anesthetic doses. However, we hypothesize 
that the molecular targets and the activation of the mechanisms that underlie the behavioral 
responses of ketamine may be similar. 
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Behavior is thought of as the sum of bottom-up influences of factors ranging from those 
existing at the level of a single cell, those involving cell to cell communication, and those 
derived from the circuits and networks that are present in the brain. However, the process of 
communication in the brain is not a strict product of information going through the anatomical 
pathways. The degree of activation of different brain regions and the synchrony between 
neural activity patterns is one of the determinants that influences brain processes and 
behavior. In our studies, we explored ketamine as a tool to modulate two behavioral 
constructs: mood and impulsivity. Ketamine, which is commonly used as a GA, has activity 
over specific receptors: it is mainly an NMDA antagonist, with known dopaminergic modulator 
activity and activator on fast acting molecular pathways responsible for its behavioral 
responses. 
The main aim of our work was to establish the potential role of the GA ketamine as a 
therapeutic agent in other areas of intervention not related with anesthesia, namely, mood 
and impulsive behavior.  
Concerning mood, we were able to show that the addition of ketamine to antidepressants 
treatment is effective in achieving a faster recovery on the antidepressant response; we also 
evaluated structural changes, and we found that addition of ketamine is especially important 
concerning dendritic spine maturation.  
When our work focused in the effect of ketamine in impulsive response we found that 
exposure to ketamine anesthesia in consecutive GAs induces a change in impulsive 
response in the VDS paradigm, with a decrease in impulsive response rate after challenged 
with variable time delays to get a reward and a parallel change in dendritic structure.  
The versatility in behavioral responses after exposure to ketamine in different settings and the 
known fast acting effect behavioral responses are striking features of this drug. Our work 
further contributes to clarify the potential use ketamine as a therapeutic agent as well as 
increase knowledge on mood and impulsive disorders. Ketamine is by itself an example that 
currently used drugs can be used to increase standard of care in domains different from those 
they were initially developed for. 
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